|
Conference/Events
|
40th Annual Healthcare… 40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link ShowHide Related Items >><< - 01/10/22
- 10X Genomics saw headwinds to business in December from omicron surge
- 07/27/21
- Bio-Rad and 10x Genomics announce settlement to resolve multiple litigations
- 07/27/21
- 10x Genomics enters into cross-license agreement with Bio-Rad
- 07/14/21
- 10x Genomics intoduces Chromium X Series for single cell analysis
- 01/10/22
- Singular Genomics partners with Twist Bioscience
- 01/05/22
- Twist Bioscience announces RBT-0813 neutralizes SARS-CoV-2 variants
- 12/16/21
- Twist Bioscience, Sosei Group announce GPCR collaboration
- 12/16/21
- Sosei Group enters agreement with Twist to discover, develop novel antibodies
- 12/08/21
- Talis Biomedical CEO Blaser steps down, CCO Kelley to succeed
- 11/08/21
- Talis Biomedical granted FDA EUA for Talis One COVID-19 Test System
- 08/30/21
- Talis Biomedical CEO Brian Coe steps down, Kim Popovits named interim CEO
- 01/10/22
- Cathie Wood's ARK Investment bought 169.5K shares of Teladoc on Monday
- 12/29/21
- Cathie Wood's ARK Investment bought 146.8K shares of Teladoc on Wednesday
- 12/28/21
- Cathie Wood's ARK Investment bought 123K shares of Teladoc on Tuesday
- 12/27/21
- Cathie Wood's ARK Investment sold 56.3K shares of Tesla on Monday
- 11/09/21
- Shattuck Labs announces preliminary clinical data from ongoing ARC trials
- 08/18/21
- Codiak appoints Lini Pandite to board of directors
- 11/30/21
- Scholar Rock announces design of phase 3 trial of Apitegromab in SMA
- 11/12/21
- Scholar Rock presents initial clinical data from Part A of DRAGON trial
- 09/28/21
- Scholar Rock announces issuance of U.S. patent protecting SRK-181
- 09/23/21
- Scholar Rock says added analyses 'further reinforce enthusiasm' for apitegromab
- 01/10/22
- Solid Biosciences outlines strategic priorities for 2022
- 01/04/22
- Solid Biosciences reports inducement grant to SVP, human resources
- 11/02/21
- Pathway Development Consortium releases draft white paper
- 09/29/21
- Solid Biosciences reports additional pulmonary function results from IGNITE DMD
- 01/10/22
- Seer, Discovery Life Sciences, SCIEX announce proteogenomics consortium
- 01/10/22
- Seer announces broad commercial release of Proteograph product suite
- 11/04/21
- Seer drops 7% to $34.15 after Bear Cave short report
- 01/04/22
- Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion
- 12/10/21
- Relay Therapeutics announces preclinical data on RLY-2608
- 10/08/21
- Relay Therapeutics trading resumes
- 10/08/21
- Relay Therapeutics trading halted, volatility trading pause
- 01/10/22
- Ultragenyx reports cash balance of $1B as of Dec. 31
- 01/07/22
- Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.
- 01/05/22
- Ultragenyx, GeneTx provide preliminary update on Phase 1/2 study of GTX-102
- 12/01/21
- Ultragenyx announces first patient dosed in Phase 1/2study of UX053
- 01/05/22
- Rain Therapeutics, Roche to collaborate on trial of milademetan combination
- 12/14/21
- Rain Therapeutics added to Nasdaq Biotechnology Index
- 11/19/21
- Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan
- 11/10/21
- Rain Therapeutics announces anticipated milestones
- 11/09/21
- Quantum-Si acquires Majelac Technologies to secure chip supply chain
- 01/06/22
- Quidel CEO says looking ahead to launch of Savanna, closing Ortho deal in 2022
- 12/28/21
- Quidel confirm its antigen tests continue to detect COVID variants like omicron
- 12/23/21
- Quidel falls 12% to $146 after announcing $6B deal to acquire Ortho Clinical
- 12/23/21
- Quidel trading resumes
- 01/11/22
- PacBio, Genomics England collaborate to sequence biobanked rare disease samples
- 01/11/22
- PacBio, Berry Genomics collaborate for long read desktop sequencing
- 01/11/22
- PacBio, Google collabare to use machine learning for data analysis
- 01/07/22
- Pacific Biosciences announces Radboudumc adds two new Sequel IIe Systems
- 01/10/22
- Singular Genomics partners with New England Biolabs
- 01/10/22
- Singular Genomics partners with Dovetail Genomics
- 01/10/22
- Singular Genomics partners with Watchmaker Genomics
- 01/04/22
- Nevro: UnitedHealth to provide coverage for company's treatment of PDN
- 12/21/21
- Nevro announces settlement of patent lawsuit with Nalu Medical
- 11/29/21
- Nevro announces 'important clinical data publications' for treating PDN with HFX
- 11/01/21
- Nevro announces update in Boston Scientific patent litigation, to pay $20M
- 01/07/22
- Neuropace Inc trading resumes
- 01/07/22
- Neuropace Inc trading halted, volatility trading pause
- 07/19/21
- Novanta buys privately held ATI Industrial Automation for $172M accretive deal
- 07/12/21
- Novanta to acquires Schneider Electric Motion USA for $115M in accretive deal
- 12/14/21
- Myriad Genetics promotes Nicole Lambert to COO
- 11/22/21
- Myriad Genetics to present new data at SABCS
- 10/18/21
- Myriad Genetics names Pamela Wong as Chief Legal Officer
- 09/07/21
- Illumina partners with Merck to develop, commercialize tests for cancer mutation
MRNS Marinus Pharmaceuticals - 12/03/21
- Marinus announces new clinical and research data to be presented at AES
- 09/20/21
- FDA accepts Marinus' filing and priority review of NDA for ganaxolone
- 08/17/21
- Marinus Pharmaceuticals reports topline ganaxolone Phase 2 results
- 08/03/21
- Marinus Pharmaceuticals submits ganaxolone NDA to FDA
- 12/12/21
- MorphoSys presents latest data from Phase 2 MANIFEST study
- 12/12/21
- MorphoSys, Incyte announce additional real-world evidence results from RE-MIND2
- 11/04/21
- MorphoSys presents interim results from M-PLACE study with felzartamab
- 11/02/21
- MorphoSys reports Q3 Monjuvi U.S. sales of $22M
- 01/10/22
- Molecular Partners, Novartis report Part A of EMPATHY trial met primary endpoint
- 12/12/21
- Molecular Partners confirms ensovibep retains Neutralization of omicron variant
- 12/06/21
- Molecular Partners presents results from ensovibep study for COVID-19 patients
- 12/03/21
- Molecular Partners enters MP0533 research collaboration with University of Bern
- 12/15/21
- ModivCare appoints Grover Wray as Chief Human Resources Officer
- 08/05/21
- Uber, ModivCare announce care-at-scale partnership
- 08/03/21
- ModivCare acquires VRI Intermediate Holdings for $315M
- 07/26/21
- ModivCare to acquire CareFinders Total Care for $340M
- $171.26 /
-1.835 (-1.06%) - 01/11/22
- FDA grants J&J request to add warning on COVID-19 Vaccine fact sheet
- 01/06/22
- Johnson & Johnson reports new results on durability of COVID-19 vaccines in U.S.
- 01/05/22
- SRI International announces collaboration agreement with Janssen
- 01/04/22
- CDC shortens Pfizer vaccine booster interval to five months from six
JAZZ Jazz Pharmaceuticals - 01/10/22
- Jazz Pharmaceuticals announces $5B revenue target for 2025
- 01/05/22
- Jazz Pharmaceuticals: Lancet Neurology publishes positive Phase 3 data of Xywav
- 01/03/22
- Jazz Pharmaceuticals: FDA grants Orphan Drug Exclusivity for Xywav
- 12/30/21
- Jazz announces first patient enrolled in Phase 2 trial of JZP150
- 12/06/21
- Inventiva reports results of QT study conducted with lanifibranor
- 10/27/21
- Inventiva announces design of LEGEND trial
- 09/21/21
- FDA extends prior fast track for lanifibranor for NASH to compensated cirrhosis
- 01/10/22
- iTeos Therapeutics announces clinical development plans
- 01/10/22
- iTeos Therapeutics appoints Yvonne McGrath as CSO
- 12/31/21
- Iteos to replace Magellan Health in S&P SmallCap 600 on 1/5
- 08/12/21
- iTeos Therapeutics expects cash to fund requirements into 2026
- 12/20/21
- Intra-Cellular jumps 18% to $46.30 after FDA approval of Caplyta
- 12/20/21
- Intra-Cellular announces FDA approval of Caplyta
- 10/18/21
- Intra-Cellular announces amended start time to October 20 virtual event
- 09/27/21
- Intra-Cellular announces publication of Phase 3 study of lumateperone
IART Integra LifeSciences - 01/11/22
- Integra LifeSciences plans $125M share repurchase
- 10/28/21
- Integra LifeSciences appoints Jan De Witte as president, CEO
- 07/19/21
- Integra LifeSciences announces 'positive' clinical outcomes for PriMatrix
HZNP Horizon Therapeutics - 01/10/22
- Horizon Therapeutics submits sBLA for concomitant use of KRYSTEXXA in gout
- 01/06/22
- Horizon Therapeutics to be tenant at Alexandria Center in Maryland
- 12/16/21
- Alpine Immune Sciences, Horizon Therapeutics enter exclusive license agreement
- 11/22/21
- Horizon Therapeutics publishes new post hoc analysis of Uplizna trial
- 01/10/22
- Gilead in trial pact with Merck to evaluate Trodelvy -Keytruda combo in NSCLC
- 12/22/21
- Gilead reports results from Phase 3 study of three-day course of Veklury
- 12/21/21
- Gilead announces clinical hold on studies of injectable Lenacapavir in HIV
- 12/21/21
- Gilead announces EC approval to variation of CMA for Veklury
- 01/04/22
- Endo's Par Pharma begins shipping first generic version of Merz's Cuvposa
- 12/23/21
- Endo announces pact to settle Texas opioid cases and claims
- 12/23/21
- Endo announces agreement for Paladin Labs to commercialize XCOPRI in Canada
- 12/15/21
- Eagle Pharmaceuticals receives FDA approval for Vasopressin
- 01/10/22
- Selecta Biosciences, Ginkgo Bioworks announced collaboration
- 01/06/22
- Cathie Wood's ARK Investment bought 2.12M shares of Ginkgo Bioworks today
- 01/06/22
- Ginkgo Bioworks, Optimvia partner to manufacture biosynthetic heparin
- 01/05/22
- Ginkgo Bioworks falls -10.3%
DAWN Day One Biopharmaceuticals - 11/22/21
- Day One announces first patient dosed in Phase 2 study of DAY101
- 09/13/21
- Day One Biopharmaceuticals appoints Jaa Roberson as CPO
- 08/17/21
- Day One Biopharmaceuticals appoints Scott Garland to board of directors
- 07/27/21
- Day One Biopharmaceuticals receives FDA Rare Pediatric Designation for DAY101
- 01/05/22
- Crinetics appoints Rogerio Vivaldi Coelho to board of directors
- 11/08/21
- Crinetics presents new data from OLE trial of paltusotine
- 10/18/21
- Crinetics forms new company for nonpeptide radiopharmaceuticals Radionetics
- 09/27/21
- Crinetics to present parathyroid receptor antagonist program at ASBMR meeting
- 10/20/21
- Viatris says Express Scripts to list Semglee as preferred on largest formulary
- 10/08/21
- Chubb to acquire life, non-life insurance companies of Cigna in APAC for $5.75B
- 10/01/21
- Cigna announces expansion of Medicare Advantage plans
- 09/28/21
- Procept BioRobotics announces Cigna adds Aquablation therapy to coverage policy
- 12/20/21
- Cerner trading resumes
- 12/20/21
- Oracle confirms agreement to acquire Cerner for $95.00 per share
- 12/20/21
- Oracle to buy Cerner for $95.00 per share in cash or $28.3B in equity value
- 12/20/21
- Cerner trading halted, news pending
- 12/23/21
- Conformis CLO, corporate secretary Brent Alldredge to depart
- 12/02/21
- Bruker says FluoroType SARS-CoV-2 varID Q assay detects all variants
- 12/02/21
- Bruker to replace KAR Auction in the S&P 400 at open on 12/2
- 12/02/21
- KAR Auction to replace Meredith in the S&P 600 at open on 12/2
- $215.88 /
-14.32 (-6.22%) - 01/11/22
- BioNTech, InstaDeep tested EWS to detect potential high-risk COVID variants
- 01/10/22
- BioNTech, Crescendo Biologics announce global collaboration
- 01/05/22
- CDC expands Pfizer, BioNTech vaccine eligibility down to age 12
- 01/05/22
- Pfizer, BioNTech to partner on first mRNA-based shingles vaccine
- 12/07/21
- Bright Health rises 20.4%
- 12/07/21
- Bright Health rises 18.5%
- 11/11/21
- Bright Health falls -25.0%
- 11/11/21
- Bright Health falls -20.5%
- 01/10/22
- Pfizer, Beam Therapeutics announce four-year research collaboration
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 11/12/21
- Beam Therapeutics reports preclinical data for multiplex edited CAR T cells
- 10/19/21
- Sana obtains non-exlusive license to CRISPR Cas12b gene editing technology
- 12/20/21
- Alcoa to replace Hill-Rom in S&P 400 at open on 12/20
- 12/09/21
- Inspira Technologies signs summary distribution agreement with Innovimed
- 12/02/21
- Hillrom shareholders approve acquisition by Baxter
- 12/23/21
- Amyris completes JV with Minerva
- 10/05/21
- Amyris licenses Onyx genome engineering platform from Inscripta
- 09/07/21
- Amyris closes acquisition of Beauty Labs
- 08/31/21
- Amyris acquires MG Empower, terms not disclosed
ALLO Allogene Therapeutics - 01/11/22
- Allogene Therapeutics announces collaboration license agreement with Antion
- 01/10/22
- Allogene Therapeutics says FDA lifts hold on clinical trials
- 01/10/22
- Allogene announces removal of FDA clinical hold across AlloCAR T trials
- 12/15/21
- Allogene Therapeutics enters lease agreement to expand headquarters
- 01/11/22
- Sarissa intends to nominate directors to Alkermes board
- 11/11/21
- Alkermes says first patient dosed in Phase 1 study of ALKS 1140
- 11/08/21
- Alkermes receives notices of partial termination from Janssen
- 10/27/21
- Alkermes reiterates its financial expectations for 2021
- 01/11/22
- AbbVie confirms combined 2025 Rinvoq and Skyrizi risk-adjusted sales of $15B+
- 01/10/22
- Frontier Medicines advances first program under AbbVie partnership
- 01/07/22
- AbbVie submits applications to FDA, EMA seeking approvals for upadacitinib
- 01/05/22
- Aspira Women's Health announces fourth quarter operational metrics, updates
- 01/11/22 Piper Sandler
- AbbVie long range estimates need to come up, says Piper Sandler
- 01/05/22 Mizuho
- Mizuho keeps AbbVie as top 2022 large cap pick, ups target
- 01/03/22 Piper Sandler
- AbbVie price target raised to $160 from $129 at Piper Sandler
- 12/17/21 Goldman Sachs
- AbbVie initiated with a Neutral at Goldman Sachs
ALLO Allogene Therapeutics - 01/10/22 Stifel
- Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
- 01/06/22 Wells Fargo
- Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
- 01/03/22 Guggenheim
- Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
- 01/03/22 B. Riley
- iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
- 01/07/22 Citi
- Baxter resumed with a Buy at Citi
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
- 01/04/22 Raymond James
- Baxter price target raised to $99 from $93 at Raymond James
- 01/10/22 Citi
- Bright Health assumed with a Neutral at Citi
- 01/07/22 Barclays
- Bright Health price target lowered to $5.50 from $9 at Barclays
- 12/17/21 Morgan Stanley
- Bright Health downgraded to Underweight at Morgan Stanley
- 12/16/21 Morgan Stanley
- Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
- 11/26/21 Benchmark
- Recent deals highlight value in ImmunoPrecise shares, says Benchmark
- 11/23/21 Baird
- Twist Bioscience price target lowered to $113 from $130 at Baird
- 10/14/21 Cowen
- Twist Bioscience coverage transferred at Cowen
- 08/09/21 Baird
- Twist Bioscience price target lowered to $130 from $140 at Baird
- 10/14/21 Cowen
- 10x Genomics coverage transferred at Cowen
- 09/14/21
- Fly Intel: Top five analyst downgrades
- 09/14/21 BofA
- 10x Genomics downgraded on 'incrementally more negative' tone at BofA
- 09/14/21 BofA
- 10x Genomics downgraded to Neutral from Buy at BofA
- 01/11/22 Piper Sandler
- Teladoc price target lowered to $118 from $183 at Piper Sandler
- 12/02/21 Baird
- Teladoc elevated to bullish Fresh Pick at Baird
- 12/01/21 Jefferies
- Teladoc assumed with a Hold at Jefferies
- 11/23/21 Canaccord
- Teladoc price target lowered to $160 from $188 at Canaccord
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold from Buy at Jefferies
- 11/18/21 Piper Sandler
- Scholar Rock initiated with an Overweight at Piper Sandler
- 06/11/21 BMO Capital
- Scholar Rock coverage transferred at BMO Capital
- 09/24/21 Chardan
- Solid Biosciences price target lowered to $17 from $20 at Chardan
- 09/23/21 Piper Sandler
- Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
- 07/12/21 Piper Sandler
- Solid Biosciences initiated with a Neutral at Piper Sandler
- 07/09/21 Chardan
- Solid Biosciences coverage transferred at Chardan
- 01/03/22 Guggenheim
- Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
- 11/08/21 Jefferies
- Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
- 08/17/21 H.C. Wainwright
- Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
- 07/21/21 BofA
- BofA starts possible 'breakout star' Relay Therapeutics at Buy
- 10/20/21 Canaccord
- Quantum-Si initiated with a Buy at Canaccord
- 12/27/21 Raymond James
- Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
- 12/27/21 H.C. Wainwright
- Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
- 12/23/21 Evercore ISI
- Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
- 12/23/21
- Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals - 06/21/21 Cowen
- Cowen starts Day One with Outperform on glioma potential
- 06/21/21 JPMorgan
- Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 01/06/22 Monness Crespi
- Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
- 12/21/21 KeyBanc
- Cerner downgraded to Sector Weight from Overweight at KeyBanc
- 12/21/21 Deutsche Bank
- Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
- 12/21/21 KeyBanc
- KeyBanc downgrades Oracle, calls Cerner deal non-strategic
- 10/14/21 Cowen
- Bruker coverage transferred at Cowen
- 08/03/21 Wells Fargo
- Bruker price target raised to $85 from $70 at Wells Fargo
- 08/03/21 Citi
- Bruker price target raised to $85 from $75 at Citi
- 06/15/21 Cleveland Research
- Bruker upgraded to Buy from Neutral at Cleveland Research
- $215.88 /
-14.32 (-6.22%) - 12/22/21 Kempen
- BioNTech upgraded to Buy from Neutral at Kempen
- 12/21/21 H.C. Wainwright
- BioNTech price target raised to $366 from $360 at H.C. Wainwright
- 12/16/21 Morgan Stanley
- BioNTech initiated with an Equal Weight at Morgan Stanley
- 12/06/21 BofA
- BioNTech price target raised to $349 from $341 at BofA
- 01/10/22 Wedbush
- Beam Therapeutics price target raised to $159 from $148 at Wedbush
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 10/19/21 SVB Leerink
- Beam Therapeutics initiated with an Outperform at SVB Leerink
- 01/04/22 JPMorgan
- MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
- 11/12/21 Morgan Stanley
- MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
- 09/27/21 Citi
- MorphoSys downgraded to Neutral from Buy at Citi
- 09/13/21 Goldman Sachs
- MorphoSys reinstated with a Neutral at Goldman Sachs
- 08/10/21 Credit Suisse
- Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
- 07/12/21 Cowen
- Molecular Partners initiated with an Outperform at Cowen
- 07/12/21 RBC Capital
- Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
- 07/12/21 SVB Leerink
- Molecular Partners assumed with an Outperform at SVB Leerink
- 12/17/21 Deutsche Bank
- ModivCare initiated with a Buy at Deutsche Bank
- 08/04/21 Barrington
- ModivCare price target raised to $186 from $170 at Barrington
- 05/10/21 Barrington
- ModivCare price target raised to $170 from $162 at Barrington
- 10/14/21 Cowen
- Myriad Genetics coverage transferred at Cowen
- 06/15/21
- Fly Intel: Top five analyst initiations
- 06/15/21 Raymond James
- Myriad Genetics initiated with a Market Perform at Raymond James
- 06/03/21 Goldman Sachs
- Myriad Genetics initiated with a Sell at Goldman Sachs
- 01/11/22 Bernstein
- Cigna price target raised to $258 from $234 at Bernstein
- 01/06/22 Wells Fargo
- Wells Fargo upgrades Cigna to Overweight, raises price target to $278
- 01/06/22 Wells Fargo
- Cigna upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/22 Truist
- Cigna price target raised to $275 from $270 at Truist
- 11/30/21 JMP Securities
- Crinetics initiated with an Outperform at JMP Securities
- 11/23/21 Evercore ISI
- Evercore starts 'rare endo treasure trove' Crinetics at Outperform
- 11/23/21 Evercore ISI
- Crinetics initiated with an Outperform at Evercore ISI
- 06/18/21 JPMorgan
- Crinetics upgraded to Overweight ahead of data at JPMorgan
- 01/06/22 BTIG
- BTIG starts Ginkgo Bioworks at Buy with $12 price target
- 01/06/22 BTIG
- Ginkgo Bioworks initiated with a Buy at BTIG
- 11/29/21 Jefferies
- Ginkgo Bioworks initiated with a Buy at Jefferies
- 10/20/21 Raymond James
- Raymond James expects more equity-based payments for Ginkgo as milestones met
- 12/16/21 Barclays
- Endo price target lowered to $5 from $7 at Barclays
- 11/05/21 Stifel
- Endo's performance tempering 'noise' around litigation, says Stifel
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral from Overweight at Piper Sandler
- $171.26 /
-1.835 (-1.06%) - 12/29/21 Credit Suisse
- Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
- 12/17/21
- Fly Intel: Top five analyst initiations
- 12/17/21 Goldman Sachs
- Goldman starts Johnson & Johnson at Neutral amid disruption risk
- 12/17/21 Goldman Sachs
- Johnson & Johnson initiated with a Neutral at Goldman Sachs
- 01/06/22 Morgan Stanley
- Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/22/21 Piper Sandler
- Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
- 12/22/21 Morgan Stanley
- Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
- 12/15/21 Jefferies
- Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
- 12/01/21 Jefferies
- Health Catalyst initiated with a Hold at Jefferies
- 10/14/21 BTIG
- Health Catalyst initiated with a Buy at BTIG
- 08/10/21 RBC Capital
- Health Catalyst price target raised to $66 from $60 at RBC Capital
- 08/06/21 Canaccord
- Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics - 12/08/21
- Fly Intel: Top five analyst initiations
- 12/08/21 Wells Fargo
- Horizon Therapeutics initiated with an Overweight at Wells Fargo
- 11/18/21 Goldman Sachs
- Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
- 10/12/21 Evercore ISI
- Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences - 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
- 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
- 12/15/21 Citi
- Integra LifeSciences price target lowered to $70 from $78 at Citi
- 10/28/21 Piper Sandler
- Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals - 12/22/21 JPMorgan
- Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
- 12/20/21 SVB Leerink
- Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
- 12/17/21 Needham
- Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
- 11/18/21 Goldman Sachs
- Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 09/22/21 H.C. Wainwright
- Inventiva price target raised to $40 from $38 at H.C. Wainwright
- 05/04/21 Roth Capital
- Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
- 03/08/21
- Fly Intel: Top five analyst downgrades
- 12/16/21 Wedbush
- iTeos Therapeutics added to 'Best Ideas List' at Wedbush
- 12/13/21 H.C. Wainwright
- iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
- 11/11/21 Piper Sandler
- iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
- 06/14/21 Piper Sandler
- iTeos deal 'addresses a number of needs all at once, says Piper Sandler
- 12/21/21 RBC Capital
- Intra-Cellular price target raised to $55 from $50 at RBC Capital
- 12/21/21 Jefferies
- Intra-Cellular price target raised to $85 from $70 at Jefferies
- 12/20/21 Canaccord
- Intra-Cellular price target raised to $88 from $81 at Canaccord
- 12/20/21 SVB Leerink
- Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals - 08/18/21 Truist
- Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
- 03/10/21 H.C. Wainwright
- Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/06/22 UBS
- Singular Genomics price target lowered to $25 from $32 at UBS
- 10/14/21 Cowen
- Singular Genomics coverage transferred at Cowen
- 01/11/22 Piper Sandler
- Pacific Biosciences has new competitor in Illumina, says Piper Sandler
- 01/05/22 Piper Sandler
- Pacific Biosciences assumed with a Neutral at Piper Sandler
- 10/14/21 Cowen
- Pacific Biosciences coverage transferred at Cowen
- 09/27/21 Canaccord
- Pacific Biosciences initiated with a Buy at Canaccord
- 01/05/22 Stifel
- Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
- 11/03/21 Citi
- Ultragenyx trading at 'significant discount to fair value,' says Citi
- 09/30/21 H.C. Wainwright
- Ultragenyx initiated with a Buy at H.C. Wainwright
- 09/27/21 Piper Sandler
- Piper 'incrementally positive' on Ultragenyx after clinical hold lift
- 01/03/22 Guggenheim
- Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
- 11/10/21 Piper Sandler
- Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
- 09/14/21 Goldman Sachs
- Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
- 11/09/21 Roth Capital
- Amyris price target lowered to $15 from $22 at Roth Capital
- 10/14/21 Cowen
- Amyris coverage transferred at Cowen
- 08/06/21 H.C. Wainwright
- Amyris price target lowered to $30 from $35 at H.C. Wainwright
- 07/06/21 HSBC
- Amyris is at 'tipping point on growth,' says HSBC
- 12/01/21 Citi
- Alkermes initiated with a Neutral at Citi
- 11/09/21 Mizuho
- Alkermes price target lowered to $33 from $36 at Mizuho
- 10/28/21 Mizuho
- Alkermes shares have 25% upside after selloff, says Mizuho
- 10/28/21 H.C. Wainwright
- Alkermes price target raised to $30 from $25 at H.C. Wainwright
- 01/07/22 Morgan Stanley
- NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
- 01/07/22 Morgan Stanley
- NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/17/21 Baird
- NeuroPace price target lowered to $20 from $23 at Baird
- 11/11/21 Morgan Stanley
- Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/07/22 Piper Sandler
- Nevro price target raised to $92 from $90 at Piper Sandler
- 01/04/22 Piper Sandler
- Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
- 10/14/21 Cowen
- Seer coverage transferred at Cowen
- 08/13/21 Morgan Stanley
- Seer price target lowered to $50 from $55 at Morgan Stanley
- 04/14/21 Berenberg
- Shattuck Labs initiated with a Buy at Berenberg
- 01/20/21 Citi
- Shattuck Labs price target raised to $75 from $36 at Citi
- 01/07/22 BofA
- Talis Biomedical downgraded to Underperform from Neutral at BofA
- 09/27/21 JPMorgan
- Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral at BTIG following CEO departure
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral from Buy at BTIG
- 11/03/21
- 10x Genomics narrows FY21 revenue view to $480M-$500M from $490M-$500M
- 11/03/21
- 10x Genomics reports Q3 EPS (15c), consensus (20c)
- 08/04/21
- 10x Genomics affirms 2021 revenue outlook $480M-$500M, consensus $496.49M
- 08/04/21
- 10x Genomics reports Q2 (10c), consensus (26c)
- 11/22/21
- Twist Bioscience sees FY22 revenue $173M-$181M, consensus $176.65M
- 11/22/21
- Twist Bioscience sees Q1 revenue $37M-$39M, consensus $38.78M
- 11/22/21
- Twist Bioscience reports Q4 EPS (84c), consensus (79c)
- 08/06/21
- Twist Bioscience raises FY21 revenue view to $129M-$132M from $121M-$129M
- 11/15/21
- Talis Biomedical reports Q3 EPS ($1.49), consensus ($1.40)
- 08/10/21
- Talis Biomedical reports Q2 EPS ($2.51), consensus (91c)
- 11/18/21
- Teladoc sees fiscal 2021 revenue $2.015B-$2.025B, consensus $2.02B
- 11/18/21
- Teladoc sees fiscal 2024 revenue above $4B
- 11/18/21
- Teladoc sees 2022 revenue $2.6B, consensus $2.58B
- 11/18/21
- Teladoc targets revenue growth of 25%-30% annually though 2024
- 11/09/21
- Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024
- 11/09/21
- Shattuck Labs reports Q3 EPS (41c), two estimates (44c)
- 11/09/21
- Scholar Rock reports Q3 EPS ($1.02), consensus (85c)
- 08/10/21
- Scholar Rock reports Q2 EPS (84c), consensus (78c)
- 11/03/21
- Solid Biosciences expects cash, cash equivalents to fund operations into Q2 2023
- 11/03/21
- Solid Biosciences reports Q3 collaborative revenue $3.5M vs. $0 last year
- 08/16/21
- Solid Biosciences reports Q2 revenue $3.6M, consensus $1.26M
- 11/09/21
- Seer reports Q3 EPS (30c), consensus (28c)
- 08/12/21
- Seer reports Q2 EPS (27c), consensus (28c)
- 11/10/21
- Relay Therapeutics reports Q3 EPS (66c), consensus (64c)
- 08/12/21
- Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c)
- 01/10/22
- Ultragenyx sees 2022 Crysvita revenue $250M-$260M
- 01/10/22
- Ultragenyx sees 2021 Crysvita revenue $191M-$193M
- 11/02/21
- Ultragenyx reports Q3 EPS ($1.08), consensus ($1.41)
- 08/02/21
- Ultragenyx reports Q2 EPS ($1.81), consensus ($1.36)
- 11/10/21
- Rain Therapeutics reports Q3 EPS (70c), consensus (48c)
- 08/10/21
- Rain Therapeutics reports Q2 EPS (39c), consensus (60c)
- 11/10/21
- Quantum-Si reports Q3 EPS (13c), one estimate (17c)
- 01/06/22
- Quidel reports preliminary Q4 revenue $633M-$637M, consensus $465.7M
- 11/04/21
- Quidel reports Q3 adjusted EPS $5.36, consensus $3.52
- 10/07/21
- Quidel sees Q3 revenue $505M-$510M, up 6%-7% from last year
- 08/10/21
- Cardinal Health partners with Abbott and Quidel to distribute COVID-19 tests
- 01/11/22
- Pacific Biosciences sees 2021 revenue $130.5M, consensus $131.27M
- 01/11/22
- Pacific Biosciences sees Q4 revenue $36M, consensus $36.58M
- 11/02/21
- Pacific Biosciences reports Q3 EPS (23c), consensus (22c)
- 08/03/21
- Pacific Biosciences reports Q2 EPS (21c), consensus (20c)
- 08/03/21
- Singular Genomics reports Q2 EPS ($1.18), consensus (20c)
- 01/10/22
- Nevro reports preliminary Q4 revenue $102.5M, consensus $96.56M
- 11/08/21
- Nevro sees Q3 EPS ($1.44), consensus (87c)
- 08/05/21
- Nevro withdraws 2021 guidance due to Covid uncertainties
- 08/04/21
- Nevro sees Q3 revenue $90M-$93M, consensus $115.35M
- 01/11/22
- NeuroPace sees FY21 revenue approximately 45.2M, consensus $44.19M
- 01/11/22
- NeuroPace sees Q4 revenue approximately $11M, consensus $10.08M
- 08/12/21
- NeuroPace sees FY21 revenue view $47M, consensus $46.95M
- 08/12/21
- NeuroPace reports Q2 EPS (48c), consensus (34c)
- 11/09/21
- Novanta sees FY21 adjusted EPS $2.55-$2.62, consensus $2.45
- 11/09/21
- Novanta sees Q4 adjusted EPS 60c-67c, consensus 65c
- 11/09/21
- Novanta reports Q3 adjusted EPS 75c, consensus 60c
- 08/10/21
- Novanta sees FY21 adjusted EPS $2.30-$2.40, consensus $2.20
- 11/02/21
- Myriad Genetics not providing Q4, 2021 financial guidance
- 11/02/21
- Myriad Genetics reports Q3 adjusted EPS (2c), consensus (2c)
- 08/03/21
- Myriad Genetics not providing Q3, 2021 financial guidance
- 08/03/21
- Myriad Genetics reports Q2 adjusted EPS 12c, consensus (9c)
MRNS Marinus Pharmaceuticals - 11/09/21
- Marinus Pharmaceuticals lowers FY21 BARDA revenues view to $6M-$8M
- 11/09/21
- Marinus Pharmaceuticals reports Q3 EPS (53c), consensus (73c)
- 08/10/21
- Marinus Pharmaceuticals reports Q2 EPS (65c), consensus (69c)
- 07/26/21
- MorphoSys narrows FY21 revenue view to EUR 155M-EUR180M from EUR 150M-EUR 200M
- 11/05/21
- ModivCare reports Q3 cont-op EPS (53c), consensus
- 08/06/21
- ModivCare reports Q2 adjusted EPS $2.13, consensus $1.28
- $171.26 /
-1.835 (-1.06%) - 10/19/21
- Johnson & Johnson raises FY21 adjusted EPS view to $9.65-$9.70 from $9.50-$9.60
- 10/19/21
- Johnson & Johnson reports Q3 adjusted EPS $2.60, consensus $2.35
- 10/18/21
- Notable companies reporting before tomorrow's open
JAZZ Jazz Pharmaceuticals - 01/10/22
- Jazz Pharmaceuticals backs FY21 revenue view $3.02B-$3.1B, consensus $3.07B
- 11/09/21
- Jazz narrows FY21 raises adjusted EPS view to $15.10-$15.80 from $13.40-$14.70
- 11/09/21
- Jazz Pharmaceuticals reports Q3 adjusted EPS $4.20, consensus $3.32
- 08/03/21
- Jazz reaffirms FY21 non-GAAP EPS view $13.40-$14.70, consensus $14.45
- 11/10/21
- iTeos Therapeutics reports Q3 EPS $1.98, consensus $4.95
- 08/12/21
- iTeos Therapeutics reports Q2 EPS (75c), consensus (41c)
- 11/09/21
- Intra-Cellular reports Q3 EPS (95c), consensus (92c)
- 08/09/21
- Intra-Cellular reports Q2 EPS (85c), consensus (80c)
IART Integra LifeSciences - 01/11/22
- Integra sees FY21 revenue $1.541B-$1.543B, consensus $1.54B
- 01/11/22
- Integra sees Q4 revenue $404M-$406M, consensus $403.94M
- 01/11/22
- Integra sees Q4 revenue $404M-$406M, consensus $403.94M
- 11/02/21
- Integra LifeSciences sees Q4 adjusted EPS 82c-86c, consensus 81c
HZNP Horizon Therapeutics - 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
- 11/09/21
- Health Catalyst sees FY21 revenue $238.6M-$241.6M, consensus $239.02M
- 11/09/21
- Health Catalyst sees Q4 revenue $61.4M-$64.4M, consensus $62.75M
- 11/09/21
- Health Catalyst reports Q EPS (18c), consensus (22c)
- 08/05/21
- Health Catalyst sees Q3 revenue $59.4M-$62.4M, consensus $58.7M
- 10/28/21
- Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25
- 10/28/21
- Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74
- 10/28/21
- Notable companies reporting after market close
- 07/29/21
- Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45
- 11/04/21
- Endo raises FY21 adjusted EPS view to $2.80-$2.85 from $2.15-$2.30
- 11/04/21
- Endo reports Q3 adjusted EPS 80c, consensus 48c
- 08/05/21
- Endo narrows FY21 adjusted EPS to $2.15-$2.30 from $1.95-$2.30
- 08/05/21
- Endo reports Q2 cont-op adjusted EPS 65c, consensus 48c
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
DAWN Day One Biopharmaceuticals - 11/08/21
- Day One Biopharmaceuticals sees cash to fund operations into 2H of 2023
- 11/08/21
- Day One Biopharmaceuticals reports Q3 EPS (33c), consensus (28c)
- 08/10/21
- Day One Biopharmaceuticals reports Q2 EPS ($5.04), consensus (31c)
- 11/05/21
- Crinetics reports Q3 EPS (73c), consensus (72c)
- 12/27/21
- Cigna still sees FY21 adjusted EPS of at least $20.35, consensus $20.40
- 11/04/21
- Cigna sees FY22 EPS up at least 10% off increased FY21 guidance
- 11/04/21
- Cigna raises FY21 adjusted EPS view to at least $20.35 from at least $20.20
- 11/04/21
- Cigna reports Q3 adjusted EPS $5.73, consensus $5.22
- 10/29/21
- Cerner raises FY21 adjusted EPS view to $3.30 from $3.25, consensus $3.26
- 10/29/21
- Cerner sees Q4 adjusted EPS growth of 10%-13% over Q4 of 2020, consensus 88c
- 10/29/21
- Cerner reports Q3 adjusted EPS 86c, consensus 82c
- 10/28/21
- Notable companies reporting before tomorrow's open
- 11/01/21
- Bruker raises FY21 adjusted EPS view to $2.05-$2.09, consensus $1.93
- 11/01/21
- Bruker reports Q3 adjusted EPS 63c, consensus 44c
- 08/02/21
- Bruker reports Q2 EPS 44c, consensus 38c
- 08/02/21
- Bruker raises FY21 EPS outlook to $1.88-$1.93, consensus 1.89
- $215.88 /
-14.32 (-6.22%) - 11/09/21
- BioNTech sees 2021 COVID-19 vaccine revenues EUR 16B - EUR 17B
- 11/09/21
- BioNTech reports Q3 EPS EUR 12.35 vs. (EUR 0.88) last year
- 08/09/21
- BioNTech sees 2021 capex EUR 175M - EUR 225M
- 08/09/21
- BioNTech reports Q2 EPS EUR 10.77 vs. (EUR 0.38) last year
- 01/10/22
- Bright Health backs FY22 revenue view $6.3B-$6.4B, consensus $6.27B
- 12/07/21
- Bright Health sees FY22 revenue $6.3B-$6.5B, consensus $5.87B
- 12/07/21
- Bright Health reaffirms FY21 revenue view of $4.1B-$4.2B, consensus $4.13B
- 11/11/21
- Bright Health sees FY21 revenue $4.1B-$4.2B, consensus $4.13B
- 11/08/21
- Beam Therapeutics reports Q3 EPS (42c), consensus (74c)
- 08/10/21
- Beam Therapeutics reports Q2 EPS ($1.23), consensus (65c)
- 10/28/21
- Baxter sees Q4 EPS $1.00-$1.04, consensus $1.02
- 10/28/21
- Baxter sees FY21 EPS $3.58 to $3.62, consensus $3.52
- 10/28/21
- Baxter reports Q3 EPS $1.02, consensus 94c
- 07/29/21
- Baxter narrows FY21 adjusted EPS view to $3.49-$3.55 from $3.47-$3.55
- 11/08/21
- Amyris reports Q3 EPS (27c) vs. (41c) last year
ALLO Allogene Therapeutics - 11/04/21
- Allogene Therapeutics reports Q3 EPS (57c), consensus (56c)
- 08/04/21
- Allogene Therapeutics reports Q2 EPS (53c), consensus (55c)
- 10/27/21
- Alkermes reports Q3 adjusted EPS 15c, consensus 6c
- 07/28/21
- Alkermes raises FY21 non-GAAP EPS to 52c-70c from 37c-62c, consensus 51c
- 07/28/21
- Alkermes reports Q2 non-GAAP EPS 30c, consensus 12c
- 10/29/21
- AbbVie sees FY21 revenue approaching $56.2B, consensus $56.28B
- 10/29/21
- AbbVie sees Q4 adjusted EPS $3.24-$3.28, consensus $3.30
- 10/29/21
- AbbVie raises FY21 adjusted EPS view to $12.63-$12.67 from $12.52-$12.62
- 10/29/21
- AbbVie reports Q3 adjusted EPS $3.33, consensus $3.22
|
|
Conference/Events
|
Meeting to be held on… Meeting to be held on January 11 hosted by Oppenheimer. ShowHide Related Items >><< - 12/23/21
- Amyris completes JV with Minerva
- 10/05/21
- Amyris licenses Onyx genome engineering platform from Inscripta
- 09/07/21
- Amyris closes acquisition of Beauty Labs
- 08/31/21
- Amyris acquires MG Empower, terms not disclosed
- 11/09/21 Roth Capital
- Amyris price target lowered to $15 from $22 at Roth Capital
- 10/14/21 Cowen
- Amyris coverage transferred at Cowen
- 08/06/21 H.C. Wainwright
- Amyris price target lowered to $30 from $35 at H.C. Wainwright
- 07/06/21 HSBC
- Amyris is at 'tipping point on growth,' says HSBC
- 11/08/21
- Amyris reports Q3 EPS (27c) vs. (41c) last year
|
|
Conference/Events
|
40th Annual Healthcare… 40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link ShowHide Related Items >><< - 01/10/22
- 10X Genomics saw headwinds to business in December from omicron surge
- 07/27/21
- Bio-Rad and 10x Genomics announce settlement to resolve multiple litigations
- 07/27/21
- 10x Genomics enters into cross-license agreement with Bio-Rad
- 07/14/21
- 10x Genomics intoduces Chromium X Series for single cell analysis
- 01/10/22
- Singular Genomics partners with Twist Bioscience
- 01/05/22
- Twist Bioscience announces RBT-0813 neutralizes SARS-CoV-2 variants
- 12/16/21
- Twist Bioscience, Sosei Group announce GPCR collaboration
- 12/16/21
- Sosei Group enters agreement with Twist to discover, develop novel antibodies
- 12/08/21
- Talis Biomedical CEO Blaser steps down, CCO Kelley to succeed
- 11/08/21
- Talis Biomedical granted FDA EUA for Talis One COVID-19 Test System
- 08/30/21
- Talis Biomedical CEO Brian Coe steps down, Kim Popovits named interim CEO
- 01/10/22
- Cathie Wood's ARK Investment bought 169.5K shares of Teladoc on Monday
- 12/29/21
- Cathie Wood's ARK Investment bought 146.8K shares of Teladoc on Wednesday
- 12/28/21
- Cathie Wood's ARK Investment bought 123K shares of Teladoc on Tuesday
- 12/27/21
- Cathie Wood's ARK Investment sold 56.3K shares of Tesla on Monday
- 11/09/21
- Shattuck Labs announces preliminary clinical data from ongoing ARC trials
- 08/18/21
- Codiak appoints Lini Pandite to board of directors
- 11/30/21
- Scholar Rock announces design of phase 3 trial of Apitegromab in SMA
- 11/12/21
- Scholar Rock presents initial clinical data from Part A of DRAGON trial
- 09/28/21
- Scholar Rock announces issuance of U.S. patent protecting SRK-181
- 09/23/21
- Scholar Rock says added analyses 'further reinforce enthusiasm' for apitegromab
- 01/10/22
- Solid Biosciences outlines strategic priorities for 2022
- 01/04/22
- Solid Biosciences reports inducement grant to SVP, human resources
- 11/02/21
- Pathway Development Consortium releases draft white paper
- 09/29/21
- Solid Biosciences reports additional pulmonary function results from IGNITE DMD
- 01/10/22
- Seer, Discovery Life Sciences, SCIEX announce proteogenomics consortium
- 01/10/22
- Seer announces broad commercial release of Proteograph product suite
- 11/04/21
- Seer drops 7% to $34.15 after Bear Cave short report
- 01/04/22
- Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion
- 12/10/21
- Relay Therapeutics announces preclinical data on RLY-2608
- 10/08/21
- Relay Therapeutics trading resumes
- 10/08/21
- Relay Therapeutics trading halted, volatility trading pause
- 01/10/22
- Ultragenyx reports cash balance of $1B as of Dec. 31
- 01/07/22
- Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.
- 01/05/22
- Ultragenyx, GeneTx provide preliminary update on Phase 1/2 study of GTX-102
- 12/01/21
- Ultragenyx announces first patient dosed in Phase 1/2study of UX053
- 01/05/22
- Rain Therapeutics, Roche to collaborate on trial of milademetan combination
- 12/14/21
- Rain Therapeutics added to Nasdaq Biotechnology Index
- 11/19/21
- Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan
- 11/10/21
- Rain Therapeutics announces anticipated milestones
- 11/09/21
- Quantum-Si acquires Majelac Technologies to secure chip supply chain
- 01/06/22
- Quidel CEO says looking ahead to launch of Savanna, closing Ortho deal in 2022
- 12/28/21
- Quidel confirm its antigen tests continue to detect COVID variants like omicron
- 12/23/21
- Quidel falls 12% to $146 after announcing $6B deal to acquire Ortho Clinical
- 12/23/21
- Quidel trading resumes
- 01/07/22
- Pacific Biosciences announces Radboudumc adds two new Sequel IIe Systems
- 01/06/22
- Pacific Biosciences expands fleet of HiFi applications with Azenta
- 01/05/22
- Pacific Biosciences, Care4Rare consortium collaborate on rare disease study
- 12/28/21
- PacBio says HiFiViral Surveillance kit performance not impacted by omicron
- 01/10/22
- Singular Genomics partners with New England Biolabs
- 01/10/22
- Singular Genomics partners with Dovetail Genomics
- 01/10/22
- Singular Genomics partners with Watchmaker Genomics
- 01/04/22
- Nevro: UnitedHealth to provide coverage for company's treatment of PDN
- 12/21/21
- Nevro announces settlement of patent lawsuit with Nalu Medical
- 11/29/21
- Nevro announces 'important clinical data publications' for treating PDN with HFX
- 11/01/21
- Nevro announces update in Boston Scientific patent litigation, to pay $20M
- 01/07/22
- Neuropace Inc trading resumes
- 01/07/22
- Neuropace Inc trading halted, volatility trading pause
- $158.87 /
-1.685 (-1.05%) - 07/19/21
- Novanta buys privately held ATI Industrial Automation for $172M accretive deal
- 07/12/21
- Novanta to acquires Schneider Electric Motion USA for $115M in accretive deal
- 12/14/21
- Myriad Genetics promotes Nicole Lambert to COO
- 11/22/21
- Myriad Genetics to present new data at SABCS
- 10/18/21
- Myriad Genetics names Pamela Wong as Chief Legal Officer
- 09/07/21
- Illumina partners with Merck to develop, commercialize tests for cancer mutation
MRNS Marinus Pharmaceuticals - 12/03/21
- Marinus announces new clinical and research data to be presented at AES
- 09/20/21
- FDA accepts Marinus' filing and priority review of NDA for ganaxolone
- 08/17/21
- Marinus Pharmaceuticals reports topline ganaxolone Phase 2 results
- 08/03/21
- Marinus Pharmaceuticals submits ganaxolone NDA to FDA
- 12/12/21
- MorphoSys presents latest data from Phase 2 MANIFEST study
- 12/12/21
- MorphoSys, Incyte announce additional real-world evidence results from RE-MIND2
- 11/04/21
- MorphoSys presents interim results from M-PLACE study with felzartamab
- 11/02/21
- MorphoSys reports Q3 Monjuvi U.S. sales of $22M
- 01/10/22
- Molecular Partners, Novartis report Part A of EMPATHY trial met primary endpoint
- 12/12/21
- Molecular Partners confirms ensovibep retains Neutralization of omicron variant
- 12/06/21
- Molecular Partners presents results from ensovibep study for COVID-19 patients
- 12/03/21
- Molecular Partners enters MP0533 research collaboration with University of Bern
- 12/15/21
- ModivCare appoints Grover Wray as Chief Human Resources Officer
- 08/05/21
- Uber, ModivCare announce care-at-scale partnership
- 08/03/21
- ModivCare acquires VRI Intermediate Holdings for $315M
- 07/26/21
- ModivCare to acquire CareFinders Total Care for $340M
- $173.10 /
-0.835 (-0.48%) - 01/06/22
- Johnson & Johnson reports new results on durability of COVID-19 vaccines in U.S.
- 01/05/22
- SRI International announces collaboration agreement with Janssen
- 01/04/22
- Genocea announces R&D collaboration, option agreement with Janssen Biotech
JAZZ Jazz Pharmaceuticals - $146.69 /
+12.22 (+9.09%) - 01/10/22
- Jazz Pharmaceuticals announces $5B revenue target for 2025
- 01/05/22
- Jazz Pharmaceuticals: Lancet Neurology publishes positive Phase 3 data of Xywav
- 01/03/22
- Jazz Pharmaceuticals: FDA grants Orphan Drug Exclusivity for Xywav
- 12/30/21
- Jazz announces first patient enrolled in Phase 2 trial of JZP150
- 12/06/21
- Inventiva reports results of QT study conducted with lanifibranor
- 10/27/21
- Inventiva announces design of LEGEND trial
- 09/21/21
- FDA extends prior fast track for lanifibranor for NASH to compensated cirrhosis
- 01/10/22
- iTeos Therapeutics announces clinical development plans
- 01/10/22
- iTeos Therapeutics appoints Yvonne McGrath as CSO
- 12/31/21
- Iteos to replace Magellan Health in S&P SmallCap 600 on 1/5
- 08/12/21
- iTeos Therapeutics expects cash to fund requirements into 2026
- 12/20/21
- Intra-Cellular jumps 18% to $46.30 after FDA approval of Caplyta
- 12/20/21
- Intra-Cellular announces FDA approval of Caplyta
- 10/18/21
- Intra-Cellular announces amended start time to October 20 virtual event
- 09/27/21
- Intra-Cellular announces publication of Phase 3 study of lumateperone
IART Integra LifeSciences - 10/28/21
- Integra LifeSciences appoints Jan De Witte as president, CEO
- 07/19/21
- Integra LifeSciences announces 'positive' clinical outcomes for PriMatrix
HZNP Horizon Therapeutics - 01/10/22
- Horizon Therapeutics submits sBLA for concomitant use of KRYSTEXXA in gout
- 01/06/22
- Horizon Therapeutics to be tenant at Alexandria Center in Maryland
- 12/16/21
- Alpine Immune Sciences, Horizon Therapeutics enter exclusive license agreement
- 11/22/21
- Horizon Therapeutics publishes new post hoc analysis of Uplizna trial
- 01/10/22
- Gilead in trial pact with Merck to evaluate Trodelvy -Keytruda combo in NSCLC
- 12/22/21
- Gilead reports results from Phase 3 study of three-day course of Veklury
- 12/21/21
- Gilead announces clinical hold on studies of injectable Lenacapavir in HIV
- 12/21/21
- Gilead announces EC approval to variation of CMA for Veklury
- 01/04/22
- Endo's Par Pharma begins shipping first generic version of Merz's Cuvposa
- 12/23/21
- Endo announces pact to settle Texas opioid cases and claims
- 12/23/21
- Endo announces agreement for Paladin Labs to commercialize XCOPRI in Canada
- 12/15/21
- Eagle Pharmaceuticals receives FDA approval for Vasopressin
- 01/10/22
- Selecta Biosciences, Ginkgo Bioworks announced collaboration
- 01/06/22
- Cathie Wood's ARK Investment bought 2.12M shares of Ginkgo Bioworks today
- 01/06/22
- Ginkgo Bioworks, Optimvia partner to manufacture biosynthetic heparin
- 01/05/22
- Ginkgo Bioworks falls -10.3%
DAWN Day One Biopharmaceuticals - 11/22/21
- Day One announces first patient dosed in Phase 2 study of DAY101
- 09/13/21
- Day One Biopharmaceuticals appoints Jaa Roberson as CPO
- 08/17/21
- Day One Biopharmaceuticals appoints Scott Garland to board of directors
- 07/27/21
- Day One Biopharmaceuticals receives FDA Rare Pediatric Designation for DAY101
- 01/05/22
- Crinetics appoints Rogerio Vivaldi Coelho to board of directors
- 11/08/21
- Crinetics presents new data from OLE trial of paltusotine
- 10/18/21
- Crinetics forms new company for nonpeptide radiopharmaceuticals Radionetics
- 09/27/21
- Crinetics to present parathyroid receptor antagonist program at ASBMR meeting
- $233.63 /
+0.465 (+0.20%) - 10/20/21
- Viatris says Express Scripts to list Semglee as preferred on largest formulary
- 10/08/21
- Chubb to acquire life, non-life insurance companies of Cigna in APAC for $5.75B
- 10/01/21
- Cigna announces expansion of Medicare Advantage plans
- 09/28/21
- Procept BioRobotics announces Cigna adds Aquablation therapy to coverage policy
- 12/20/21
- Cerner trading resumes
- 12/20/21
- Oracle confirms agreement to acquire Cerner for $95.00 per share
- 12/20/21
- Oracle to buy Cerner for $95.00 per share in cash or $28.3B in equity value
- 12/20/21
- Cerner trading halted, news pending
- 12/23/21
- Conformis CLO, corporate secretary Brent Alldredge to depart
- 12/02/21
- Bruker says FluoroType SARS-CoV-2 varID Q assay detects all variants
- 12/02/21
- Bruker to replace KAR Auction in the S&P 400 at open on 12/2
- 12/02/21
- KAR Auction to replace Meredith in the S&P 600 at open on 12/2
- $230.20 /
+18.37 (+8.67%) - 01/10/22
- BioNTech, Crescendo Biologics announce global collaboration
- 01/05/22
- CDC expands Pfizer, BioNTech vaccine eligibility down to age 12
- 01/05/22
- Pfizer, BioNTech to partner on first mRNA-based shingles vaccine
- 01/04/22
- CDC shortens Pfizer vaccine booster interval to five months from six
- 12/07/21
- Bright Health rises 20.4%
- 12/07/21
- Bright Health rises 18.5%
- 11/11/21
- Bright Health falls -25.0%
- 11/11/21
- Bright Health falls -20.5%
- 01/10/22
- Pfizer, Beam Therapeutics announce four-year research collaboration
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 11/12/21
- Beam Therapeutics reports preclinical data for multiplex edited CAR T cells
- 10/19/21
- Sana obtains non-exlusive license to CRISPR Cas12b gene editing technology
- 12/20/21
- Alcoa to replace Hill-Rom in S&P 400 at open on 12/20
- 12/09/21
- Inspira Technologies signs summary distribution agreement with Innovimed
- 12/02/21
- Hillrom shareholders approve acquisition by Baxter
- 12/23/21
- Amyris completes JV with Minerva
- 10/05/21
- Amyris licenses Onyx genome engineering platform from Inscripta
- 09/07/21
- Amyris closes acquisition of Beauty Labs
- 08/31/21
- Amyris acquires MG Empower, terms not disclosed
ALLO Allogene Therapeutics - 01/10/22
- Allogene Therapeutics says FDA lifts hold on clinical trials
- 01/10/22
- Allogene announces removal of FDA clinical hold across AlloCAR T trials
- 12/15/21
- Allogene Therapeutics enters lease agreement to expand headquarters
- 12/01/21
- Allogene announces call to review ALPHA, ALPHA2, UNIVERSAL data
- 11/11/21
- Alkermes says first patient dosed in Phase 1 study of ALKS 1140
- 11/08/21
- Alkermes receives notices of partial termination from Janssen
- 10/27/21
- Alkermes reiterates its financial expectations for 2021
- 10/26/21
- Alkermes begins ARTISTRY-7 phase 3 trial
- 01/10/22
- Frontier Medicines advances first program under AbbVie partnership
- 01/07/22
- AbbVie submits applications to FDA, EMA seeking approvals for upadacitinib
- 01/05/22
- Aspira Women's Health announces fourth quarter operational metrics, updates
- 01/05/22
- Organon and Samsung Bioepis' sBLA for SB5 accepted by FDA
- 01/05/22 Mizuho
- Mizuho keeps AbbVie as top 2022 large cap pick, ups target
- 01/03/22 Piper Sandler
- AbbVie price target raised to $160 from $129 at Piper Sandler
- 12/17/21 Goldman Sachs
- AbbVie initiated with a Neutral at Goldman Sachs
- 12/08/21 Wells Fargo
- Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
ALLO Allogene Therapeutics - 01/10/22 Stifel
- Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
- 01/06/22 Wells Fargo
- Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
- 01/03/22 Guggenheim
- Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
- 01/03/22 B. Riley
- iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
- 01/07/22 Citi
- Baxter resumed with a Buy at Citi
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
- 01/04/22 Raymond James
- Baxter price target raised to $99 from $93 at Raymond James
- 01/10/22 Citi
- Bright Health assumed with a Neutral at Citi
- 01/07/22 Barclays
- Bright Health price target lowered to $5.50 from $9 at Barclays
- 12/17/21 Morgan Stanley
- Bright Health downgraded to Underweight at Morgan Stanley
- 12/16/21 Morgan Stanley
- Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
- 11/26/21 Benchmark
- Recent deals highlight value in ImmunoPrecise shares, says Benchmark
- 11/23/21 Baird
- Twist Bioscience price target lowered to $113 from $130 at Baird
- 10/14/21 Cowen
- Twist Bioscience coverage transferred at Cowen
- 08/09/21 Baird
- Twist Bioscience price target lowered to $130 from $140 at Baird
- 10/14/21 Cowen
- 10x Genomics coverage transferred at Cowen
- 09/14/21
- Fly Intel: Top five analyst downgrades
- 09/14/21 BofA
- 10x Genomics downgraded on 'incrementally more negative' tone at BofA
- 09/14/21 BofA
- 10x Genomics downgraded to Neutral from Buy at BofA
- 01/11/22 Piper Sandler
- Teladoc price target lowered to $118 from $183 at Piper Sandler
- 12/02/21 Baird
- Teladoc elevated to bullish Fresh Pick at Baird
- 12/01/21 Jefferies
- Teladoc assumed with a Hold at Jefferies
- 11/23/21 Canaccord
- Teladoc price target lowered to $160 from $188 at Canaccord
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold from Buy at Jefferies
- 11/18/21 Piper Sandler
- Scholar Rock initiated with an Overweight at Piper Sandler
- 06/11/21 BMO Capital
- Scholar Rock coverage transferred at BMO Capital
- 09/24/21 Chardan
- Solid Biosciences price target lowered to $17 from $20 at Chardan
- 09/23/21 Piper Sandler
- Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
- 07/12/21 Piper Sandler
- Solid Biosciences initiated with a Neutral at Piper Sandler
- 07/09/21 Chardan
- Solid Biosciences coverage transferred at Chardan
- 01/03/22 Guggenheim
- Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
- 11/08/21 Jefferies
- Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
- 08/17/21 H.C. Wainwright
- Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
- 07/21/21 BofA
- BofA starts possible 'breakout star' Relay Therapeutics at Buy
- 10/20/21 Canaccord
- Quantum-Si initiated with a Buy at Canaccord
- 12/27/21 Raymond James
- Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
- 12/27/21 H.C. Wainwright
- Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
- 12/23/21 Evercore ISI
- Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
- 12/23/21
- Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals - 06/21/21 Cowen
- Cowen starts Day One with Outperform on glioma potential
- 06/21/21 JPMorgan
- Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 01/06/22 Monness Crespi
- Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
- 12/21/21 KeyBanc
- Cerner downgraded to Sector Weight from Overweight at KeyBanc
- 12/21/21 Deutsche Bank
- Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
- 12/21/21 KeyBanc
- KeyBanc downgrades Oracle, calls Cerner deal non-strategic
- 10/14/21 Cowen
- Bruker coverage transferred at Cowen
- 08/03/21 Wells Fargo
- Bruker price target raised to $85 from $70 at Wells Fargo
- 08/03/21 Citi
- Bruker price target raised to $85 from $75 at Citi
- 06/15/21 Cleveland Research
- Bruker upgraded to Buy from Neutral at Cleveland Research
- $230.20 /
+18.37 (+8.67%) - 12/22/21 Kempen
- BioNTech upgraded to Buy from Neutral at Kempen
- 12/21/21 H.C. Wainwright
- BioNTech price target raised to $366 from $360 at H.C. Wainwright
- 12/16/21 Morgan Stanley
- BioNTech initiated with an Equal Weight at Morgan Stanley
- 12/06/21 BofA
- BioNTech price target raised to $349 from $341 at BofA
- 01/10/22 Wedbush
- Beam Therapeutics price target raised to $159 from $148 at Wedbush
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 10/19/21 SVB Leerink
- Beam Therapeutics initiated with an Outperform at SVB Leerink
- 01/04/22 JPMorgan
- MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
- 11/12/21 Morgan Stanley
- MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
- 09/27/21 Citi
- MorphoSys downgraded to Neutral from Buy at Citi
- 09/13/21 Goldman Sachs
- MorphoSys reinstated with a Neutral at Goldman Sachs
- 08/10/21 Credit Suisse
- Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
- 07/12/21 Cowen
- Molecular Partners initiated with an Outperform at Cowen
- 07/12/21 RBC Capital
- Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
- 07/12/21 SVB Leerink
- Molecular Partners assumed with an Outperform at SVB Leerink
- 12/17/21 Deutsche Bank
- ModivCare initiated with a Buy at Deutsche Bank
- 08/04/21 Barrington
- ModivCare price target raised to $186 from $170 at Barrington
- 05/10/21 Barrington
- ModivCare price target raised to $170 from $162 at Barrington
- 10/14/21 Cowen
- Myriad Genetics coverage transferred at Cowen
- 06/15/21
- Fly Intel: Top five analyst initiations
- 06/15/21 Raymond James
- Myriad Genetics initiated with a Market Perform at Raymond James
- 06/03/21 Goldman Sachs
- Myriad Genetics initiated with a Sell at Goldman Sachs
- $233.63 /
+0.465 (+0.20%) - 01/06/22 Wells Fargo
- Wells Fargo upgrades Cigna to Overweight, raises price target to $278
- 01/06/22 Wells Fargo
- Cigna upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/22 Truist
- Cigna price target raised to $275 from $270 at Truist
- 12/21/21
- Fly Intel: Top five analyst downgrades
- 11/30/21 JMP Securities
- Crinetics initiated with an Outperform at JMP Securities
- 11/23/21 Evercore ISI
- Evercore starts 'rare endo treasure trove' Crinetics at Outperform
- 11/23/21 Evercore ISI
- Crinetics initiated with an Outperform at Evercore ISI
- 06/18/21 JPMorgan
- Crinetics upgraded to Overweight ahead of data at JPMorgan
- 01/06/22 BTIG
- BTIG starts Ginkgo Bioworks at Buy with $12 price target
- 01/06/22 BTIG
- Ginkgo Bioworks initiated with a Buy at BTIG
- 11/29/21 Jefferies
- Ginkgo Bioworks initiated with a Buy at Jefferies
- 10/20/21 Raymond James
- Raymond James expects more equity-based payments for Ginkgo as milestones met
- 12/16/21 Barclays
- Endo price target lowered to $5 from $7 at Barclays
- 11/05/21 Stifel
- Endo's performance tempering 'noise' around litigation, says Stifel
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral from Overweight at Piper Sandler
- $173.10 /
-0.835 (-0.48%) - 12/29/21 Credit Suisse
- Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
- 12/17/21
- Fly Intel: Top five analyst initiations
- 12/17/21 Goldman Sachs
- Goldman starts Johnson & Johnson at Neutral amid disruption risk
- 12/17/21 Goldman Sachs
- Johnson & Johnson initiated with a Neutral at Goldman Sachs
- 01/06/22 Morgan Stanley
- Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/22/21 Piper Sandler
- Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
- 12/22/21 Morgan Stanley
- Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
- 12/15/21 Jefferies
- Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
- 12/01/21 Jefferies
- Health Catalyst initiated with a Hold at Jefferies
- 10/14/21 BTIG
- Health Catalyst initiated with a Buy at BTIG
- 08/10/21 RBC Capital
- Health Catalyst price target raised to $66 from $60 at RBC Capital
- 08/06/21 Canaccord
- Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics - 12/08/21
- Fly Intel: Top five analyst initiations
- 12/08/21 Wells Fargo
- Horizon Therapeutics initiated with an Overweight at Wells Fargo
- 11/18/21 Goldman Sachs
- Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
- 10/12/21 Evercore ISI
- Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences - 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
- 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
- 12/15/21 Citi
- Integra LifeSciences price target lowered to $70 from $78 at Citi
- 10/28/21 Piper Sandler
- Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals - $146.69 /
+12.22 (+9.09%) - 12/22/21 JPMorgan
- Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
- 12/20/21 SVB Leerink
- Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
- 12/17/21 Needham
- Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
- 11/18/21 Goldman Sachs
- Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 09/22/21 H.C. Wainwright
- Inventiva price target raised to $40 from $38 at H.C. Wainwright
- 05/04/21 Roth Capital
- Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
- 03/08/21
- Fly Intel: Top five analyst downgrades
- 12/16/21 Wedbush
- iTeos Therapeutics added to 'Best Ideas List' at Wedbush
- 12/13/21 H.C. Wainwright
- iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
- 11/11/21 Piper Sandler
- iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
- 06/14/21 Piper Sandler
- iTeos deal 'addresses a number of needs all at once, says Piper Sandler
- 12/21/21 RBC Capital
- Intra-Cellular price target raised to $55 from $50 at RBC Capital
- 12/21/21 Jefferies
- Intra-Cellular price target raised to $85 from $70 at Jefferies
- 12/20/21 Canaccord
- Intra-Cellular price target raised to $88 from $81 at Canaccord
- 12/20/21 SVB Leerink
- Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals - 08/18/21 Truist
- Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
- 03/10/21 H.C. Wainwright
- Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
- $158.87 /
-1.685 (-1.05%) - 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/06/22 UBS
- Singular Genomics price target lowered to $25 from $32 at UBS
- 10/14/21 Cowen
- Singular Genomics coverage transferred at Cowen
- 01/05/22 Piper Sandler
- Pacific Biosciences assumed with a Neutral at Piper Sandler
- 10/14/21 Cowen
- Pacific Biosciences coverage transferred at Cowen
- 09/27/21 Canaccord
- Pacific Biosciences initiated with a Buy at Canaccord
- 03/31/21 Piper Sandler
- Illumina should be bought on weakness from FTC challenge, says Piper Sandler
- 01/05/22 Stifel
- Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
- 11/03/21 Citi
- Ultragenyx trading at 'significant discount to fair value,' says Citi
- 09/30/21 H.C. Wainwright
- Ultragenyx initiated with a Buy at H.C. Wainwright
- 09/27/21 Piper Sandler
- Piper 'incrementally positive' on Ultragenyx after clinical hold lift
- 01/03/22 Guggenheim
- Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
- 11/10/21 Piper Sandler
- Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
- 09/14/21 Goldman Sachs
- Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
- 11/09/21 Roth Capital
- Amyris price target lowered to $15 from $22 at Roth Capital
- 10/14/21 Cowen
- Amyris coverage transferred at Cowen
- 08/06/21 H.C. Wainwright
- Amyris price target lowered to $30 from $35 at H.C. Wainwright
- 07/06/21 HSBC
- Amyris is at 'tipping point on growth,' says HSBC
- 12/01/21 Citi
- Alkermes initiated with a Neutral at Citi
- 11/09/21 Mizuho
- Alkermes price target lowered to $33 from $36 at Mizuho
- 10/28/21 Mizuho
- Alkermes shares have 25% upside after selloff, says Mizuho
- 10/28/21 H.C. Wainwright
- Alkermes price target raised to $30 from $25 at H.C. Wainwright
- 01/07/22 Morgan Stanley
- NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
- 01/07/22 Morgan Stanley
- NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/17/21 Baird
- NeuroPace price target lowered to $20 from $23 at Baird
- 11/11/21 Morgan Stanley
- Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/07/22 Piper Sandler
- Nevro price target raised to $92 from $90 at Piper Sandler
- 01/04/22 Piper Sandler
- Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
- 10/14/21 Cowen
- Seer coverage transferred at Cowen
- 08/13/21 Morgan Stanley
- Seer price target lowered to $50 from $55 at Morgan Stanley
- 04/14/21 Berenberg
- Shattuck Labs initiated with a Buy at Berenberg
- 01/20/21 Citi
- Shattuck Labs price target raised to $75 from $36 at Citi
- 01/11/21 Evercore ISI
- Shattuck Labs initiated with an Outperform at Evercore ISI
- 01/07/22 BofA
- Talis Biomedical downgraded to Underperform from Neutral at BofA
- 09/27/21 JPMorgan
- Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral at BTIG following CEO departure
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral from Buy at BTIG
- 11/03/21
- 10x Genomics narrows FY21 revenue view to $480M-$500M from $490M-$500M
- 11/03/21
- 10x Genomics reports Q3 EPS (15c), consensus (20c)
- 08/04/21
- 10x Genomics affirms 2021 revenue outlook $480M-$500M, consensus $496.49M
- 08/04/21
- 10x Genomics reports Q2 (10c), consensus (26c)
- 11/22/21
- Twist Bioscience sees FY22 revenue $173M-$181M, consensus $176.65M
- 11/22/21
- Twist Bioscience sees Q1 revenue $37M-$39M, consensus $38.78M
- 11/22/21
- Twist Bioscience reports Q4 EPS (84c), consensus (79c)
- 08/06/21
- Twist Bioscience raises FY21 revenue view to $129M-$132M from $121M-$129M
- 11/15/21
- Talis Biomedical reports Q3 EPS ($1.49), consensus ($1.40)
- 08/10/21
- Talis Biomedical reports Q2 EPS ($2.51), consensus (91c)
- 11/18/21
- Teladoc sees fiscal 2021 revenue $2.015B-$2.025B, consensus $2.02B
- 11/18/21
- Teladoc sees fiscal 2024 revenue above $4B
- 11/18/21
- Teladoc sees 2022 revenue $2.6B, consensus $2.58B
- 11/18/21
- Teladoc targets revenue growth of 25%-30% annually though 2024
- 11/09/21
- Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024
- 11/09/21
- Shattuck Labs reports Q3 EPS (41c), two estimates (44c)
- 11/09/21
- Scholar Rock reports Q3 EPS ($1.02), consensus (85c)
- 08/10/21
- Scholar Rock reports Q2 EPS (84c), consensus (78c)
- 11/03/21
- Solid Biosciences expects cash, cash equivalents to fund operations into Q2 2023
- 11/03/21
- Solid Biosciences reports Q3 collaborative revenue $3.5M vs. $0 last year
- 08/16/21
- Solid Biosciences reports Q2 revenue $3.6M, consensus $1.26M
- 11/09/21
- Seer reports Q3 EPS (30c), consensus (28c)
- 08/12/21
- Seer reports Q2 EPS (27c), consensus (28c)
- 11/10/21
- Relay Therapeutics reports Q3 EPS (66c), consensus (64c)
- 08/12/21
- Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c)
- 01/10/22
- Ultragenyx sees 2022 Crysvita revenue $250M-$260M
- 01/10/22
- Ultragenyx sees 2021 Crysvita revenue $191M-$193M
- 11/02/21
- Ultragenyx reports Q3 EPS ($1.08), consensus ($1.41)
- 08/02/21
- Ultragenyx reports Q2 EPS ($1.81), consensus ($1.36)
- 11/10/21
- Rain Therapeutics reports Q3 EPS (70c), consensus (48c)
- 08/10/21
- Rain Therapeutics reports Q2 EPS (39c), consensus (60c)
- 11/10/21
- Quantum-Si reports Q3 EPS (13c), one estimate (17c)
- 01/06/22
- Quidel reports preliminary Q4 revenue $633M-$637M, consensus $465.7M
- 11/04/21
- Quidel reports Q3 adjusted EPS $5.36, consensus $3.52
- 10/07/21
- Quidel sees Q3 revenue $505M-$510M, up 6%-7% from last year
- 08/10/21
- Cardinal Health partners with Abbott and Quidel to distribute COVID-19 tests
- 11/02/21
- Pacific Biosciences reports Q3 EPS (23c), consensus (22c)
- 08/03/21
- Pacific Biosciences reports Q2 EPS (21c), consensus (20c)
- 08/03/21
- Singular Genomics reports Q2 EPS ($1.18), consensus (20c)
- 01/10/22
- Nevro reports preliminary Q4 revenue $102.5M, consensus $96.56M
- 11/08/21
- Nevro sees Q3 EPS ($1.44), consensus (87c)
- 08/05/21
- Nevro withdraws 2021 guidance due to Covid uncertainties
- 08/04/21
- Nevro sees Q3 revenue $90M-$93M, consensus $115.35M
- 08/12/21
- NeuroPace sees FY21 revenue view $47M, consensus $46.95M
- 08/12/21
- NeuroPace reports Q2 EPS (48c), consensus (34c)
- $158.87 /
-1.685 (-1.05%) - 11/09/21
- Novanta sees FY21 adjusted EPS $2.55-$2.62, consensus $2.45
- 11/09/21
- Novanta sees Q4 adjusted EPS 60c-67c, consensus 65c
- 11/09/21
- Novanta reports Q3 adjusted EPS 75c, consensus 60c
- 08/10/21
- Novanta sees FY21 adjusted EPS $2.30-$2.40, consensus $2.20
- 11/02/21
- Myriad Genetics not providing Q4, 2021 financial guidance
- 11/02/21
- Myriad Genetics reports Q3 adjusted EPS (2c), consensus (2c)
- 08/03/21
- Myriad Genetics not providing Q3, 2021 financial guidance
- 08/03/21
- Myriad Genetics reports Q2 adjusted EPS 12c, consensus (9c)
MRNS Marinus Pharmaceuticals - 11/09/21
- Marinus Pharmaceuticals lowers FY21 BARDA revenues view to $6M-$8M
- 11/09/21
- Marinus Pharmaceuticals reports Q3 EPS (53c), consensus (73c)
- 08/10/21
- Marinus Pharmaceuticals reports Q2 EPS (65c), consensus (69c)
- 07/26/21
- MorphoSys narrows FY21 revenue view to EUR 155M-EUR180M from EUR 150M-EUR 200M
- 11/05/21
- ModivCare reports Q3 cont-op EPS (53c), consensus
- 08/06/21
- ModivCare reports Q2 adjusted EPS $2.13, consensus $1.28
- $173.10 /
-0.835 (-0.48%) - 10/19/21
- Johnson & Johnson raises FY21 adjusted EPS view to $9.65-$9.70 from $9.50-$9.60
- 10/19/21
- Johnson & Johnson reports Q3 adjusted EPS $2.60, consensus $2.35
- 10/18/21
- Notable companies reporting before tomorrow's open
JAZZ Jazz Pharmaceuticals - $146.69 /
+12.22 (+9.09%) - 01/10/22
- Jazz Pharmaceuticals backs FY21 revenue view $3.02B-$3.1B, consensus $3.07B
- 11/09/21
- Jazz narrows FY21 raises adjusted EPS view to $15.10-$15.80 from $13.40-$14.70
- 11/09/21
- Jazz Pharmaceuticals reports Q3 adjusted EPS $4.20, consensus $3.32
- 08/03/21
- Jazz reaffirms FY21 non-GAAP EPS view $13.40-$14.70, consensus $14.45
- 11/10/21
- iTeos Therapeutics reports Q3 EPS $1.98, consensus $4.95
- 08/12/21
- iTeos Therapeutics reports Q2 EPS (75c), consensus (41c)
- 11/09/21
- Intra-Cellular reports Q3 EPS (95c), consensus (92c)
- 08/09/21
- Intra-Cellular reports Q2 EPS (85c), consensus (80c)
IART Integra LifeSciences - 11/02/21
- Integra LifeSciences sees Q4 adjusted EPS 82c-86c, consensus 81c
- 11/02/21
- Integra LifeSciences raises FY21 EPS view to $3.16-$3.20 from $2.98-$3.05
- 11/02/21
- Integra LifeSciences reports Q3 adjusted EPS 86c, consensus 72c
- 07/28/21
- Integra LifeSciences sees Q3 adjusted EPS 71c-74c, consensus 74c
HZNP Horizon Therapeutics - 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
- 11/09/21
- Health Catalyst sees FY21 revenue $238.6M-$241.6M, consensus $239.02M
- 11/09/21
- Health Catalyst sees Q4 revenue $61.4M-$64.4M, consensus $62.75M
- 11/09/21
- Health Catalyst reports Q EPS (18c), consensus (22c)
- 08/05/21
- Health Catalyst sees Q3 revenue $59.4M-$62.4M, consensus $58.7M
- 10/28/21
- Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25
- 10/28/21
- Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74
- 10/28/21
- Notable companies reporting after market close
- 07/29/21
- Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45
- 11/04/21
- Endo raises FY21 adjusted EPS view to $2.80-$2.85 from $2.15-$2.30
- 11/04/21
- Endo reports Q3 adjusted EPS 80c, consensus 48c
- 08/05/21
- Endo narrows FY21 adjusted EPS to $2.15-$2.30 from $1.95-$2.30
- 08/05/21
- Endo reports Q2 cont-op adjusted EPS 65c, consensus 48c
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
DAWN Day One Biopharmaceuticals - 11/08/21
- Day One Biopharmaceuticals sees cash to fund operations into 2H of 2023
- 11/08/21
- Day One Biopharmaceuticals reports Q3 EPS (33c), consensus (28c)
- 08/10/21
- Day One Biopharmaceuticals reports Q2 EPS ($5.04), consensus (31c)
- 11/05/21
- Crinetics reports Q3 EPS (73c), consensus (72c)
- $233.63 /
+0.465 (+0.20%) - 12/27/21
- Cigna still sees FY21 adjusted EPS of at least $20.35, consensus $20.40
- 11/04/21
- Cigna sees FY22 EPS up at least 10% off increased FY21 guidance
- 11/04/21
- Cigna raises FY21 adjusted EPS view to at least $20.35 from at least $20.20
- 11/04/21
- Cigna reports Q3 adjusted EPS $5.73, consensus $5.22
- 10/29/21
- Cerner raises FY21 adjusted EPS view to $3.30 from $3.25, consensus $3.26
- 10/29/21
- Cerner sees Q4 adjusted EPS growth of 10%-13% over Q4 of 2020, consensus 88c
- 10/29/21
- Cerner reports Q3 adjusted EPS 86c, consensus 82c
- 10/28/21
- Notable companies reporting before tomorrow's open
- 11/01/21
- Bruker raises FY21 adjusted EPS view to $2.05-$2.09, consensus $1.93
- 11/01/21
- Bruker reports Q3 adjusted EPS 63c, consensus 44c
- 08/02/21
- Bruker reports Q2 EPS 44c, consensus 38c
- 08/02/21
- Bruker raises FY21 EPS outlook to $1.88-$1.93, consensus 1.89
- $230.20 /
+18.37 (+8.67%) - 11/09/21
- BioNTech sees 2021 COVID-19 vaccine revenues EUR 16B - EUR 17B
- 11/09/21
- BioNTech reports Q3 EPS EUR 12.35 vs. (EUR 0.88) last year
- 08/09/21
- BioNTech sees 2021 capex EUR 175M - EUR 225M
- 08/09/21
- BioNTech reports Q2 EPS EUR 10.77 vs. (EUR 0.38) last year
- 01/10/22
- Bright Health backs FY22 revenue view $6.3B-$6.4B, consensus $6.27B
- 12/07/21
- Bright Health sees FY22 revenue $6.3B-$6.5B, consensus $5.87B
- 12/07/21
- Bright Health reaffirms FY21 revenue view of $4.1B-$4.2B, consensus $4.13B
- 11/11/21
- Bright Health sees FY21 revenue $4.1B-$4.2B, consensus $4.13B
- 11/08/21
- Beam Therapeutics reports Q3 EPS (42c), consensus (74c)
- 08/10/21
- Beam Therapeutics reports Q2 EPS ($1.23), consensus (65c)
- 10/28/21
- Baxter sees Q4 EPS $1.00-$1.04, consensus $1.02
- 10/28/21
- Baxter sees FY21 EPS $3.58 to $3.62, consensus $3.52
- 10/28/21
- Baxter reports Q3 EPS $1.02, consensus 94c
- 07/29/21
- Baxter narrows FY21 adjusted EPS view to $3.49-$3.55 from $3.47-$3.55
- 11/08/21
- Amyris reports Q3 EPS (27c) vs. (41c) last year
ALLO Allogene Therapeutics - 11/04/21
- Allogene Therapeutics reports Q3 EPS (57c), consensus (56c)
- 08/04/21
- Allogene Therapeutics reports Q2 EPS (53c), consensus (55c)
- 10/27/21
- Alkermes reports Q3 adjusted EPS 15c, consensus 6c
- 07/28/21
- Alkermes raises FY21 non-GAAP EPS to 52c-70c from 37c-62c, consensus 51c
- 07/28/21
- Alkermes reports Q2 non-GAAP EPS 30c, consensus 12c
- 10/29/21
- AbbVie sees FY21 revenue approaching $56.2B, consensus $56.28B
- 10/29/21
- AbbVie sees Q4 adjusted EPS $3.24-$3.28, consensus $3.30
- 10/29/21
- AbbVie raises FY21 adjusted EPS view to $12.63-$12.67 from $12.52-$12.62
- 10/29/21
- AbbVie reports Q3 adjusted EPS $3.33, consensus $3.22
|
|
Conference/Events
|
40th Annual Healthcare… 40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link ShowHide Related Items >><< - 07/27/21
- Bio-Rad and 10x Genomics announce settlement to resolve multiple litigations
- 07/27/21
- 10x Genomics enters into cross-license agreement with Bio-Rad
- 07/14/21
- 10x Genomics intoduces Chromium X Series for single cell analysis
- 01/05/22
- Twist Bioscience announces RBT-0813 neutralizes SARS-CoV-2 variants
- 12/16/21
- Twist Bioscience, Sosei Group announce GPCR collaboration
- 12/16/21
- Sosei Group enters agreement with Twist to discover, develop novel antibodies
- 12/15/21
- Twist shipping synthetic RNA positive controls for Omicron diagnostic tests
- 12/08/21
- Talis Biomedical CEO Blaser steps down, CCO Kelley to succeed
- 11/08/21
- Talis Biomedical granted FDA EUA for Talis One COVID-19 Test System
- 08/30/21
- Talis Biomedical CEO Brian Coe steps down, Kim Popovits named interim CEO
- 12/29/21
- Cathie Wood's ARK Investment bought 146.8K shares of Teladoc on Wednesday
- 12/28/21
- Cathie Wood's ARK Investment bought 123K shares of Teladoc on Tuesday
- 12/27/21
- Cathie Wood's ARK Investment sold 56.3K shares of Tesla on Monday
- 12/17/21
- Teladoc rises 10.6%
- 11/09/21
- Shattuck Labs announces preliminary clinical data from ongoing ARC trials
- 08/18/21
- Codiak appoints Lini Pandite to board of directors
- 11/30/21
- Scholar Rock announces design of phase 3 trial of Apitegromab in SMA
- 11/12/21
- Scholar Rock presents initial clinical data from Part A of DRAGON trial
- 09/28/21
- Scholar Rock announces issuance of U.S. patent protecting SRK-181
- 09/23/21
- Scholar Rock says added analyses 'further reinforce enthusiasm' for apitegromab
- 01/04/22
- Solid Biosciences reports inducement grant to SVP, human resources
- 11/02/21
- Pathway Development Consortium releases draft white paper
- 09/29/21
- Solid Biosciences reports additional pulmonary function results from IGNITE DMD
- 09/23/21
- Solid Biosciences' SGT-001 shows positive efficacy data at 1.5-year trial
- 11/04/21
- Seer drops 7% to $34.15 after Bear Cave short report
- 01/04/22
- Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion
- 12/10/21
- Relay Therapeutics announces preclinical data on RLY-2608
- 10/08/21
- Relay Therapeutics trading resumes
- 10/08/21
- Relay Therapeutics trading halted, volatility trading pause
- 01/07/22
- Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.
- 01/05/22
- Ultragenyx, GeneTx provide preliminary update on Phase 1/2 study of GTX-102
- 12/01/21
- Ultragenyx announces first patient dosed in Phase 1/2study of UX053
- 11/29/21
- Ultragenyx announces durability data from Phase 1/2 AAV gene therapy studies
- 01/05/22
- Rain Therapeutics, Roche to collaborate on trial of milademetan combination
- 12/14/21
- Rain Therapeutics added to Nasdaq Biotechnology Index
- 11/19/21
- Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan
- 11/10/21
- Rain Therapeutics announces anticipated milestones
- 11/09/21
- Quantum-Si acquires Majelac Technologies to secure chip supply chain
- 01/06/22
- Quidel CEO says looking ahead to launch of Savanna, closing Ortho deal in 2022
- 12/28/21
- Quidel confirm its antigen tests continue to detect COVID variants like omicron
- 12/23/21
- Quidel falls 12% to $146 after announcing $6B deal to acquire Ortho Clinical
- 12/23/21
- Quidel trading resumes
- 01/07/22
- Pacific Biosciences announces Radboudumc adds two new Sequel IIe Systems
- 01/06/22
- Pacific Biosciences expands fleet of HiFi applications with Azenta
- 01/05/22
- Pacific Biosciences, Care4Rare consortium collaborate on rare disease study
- 12/28/21
- PacBio says HiFiViral Surveillance kit performance not impacted by omicron
- 01/06/22
- Singular Genomics, Broad Institute partner to integrate technology in Terra
- 12/16/21
- Singular Genomics launches the G4 sequencing platform
- 01/04/22
- Nevro: UnitedHealth to provide coverage for company's treatment of PDN
- 12/21/21
- Nevro announces settlement of patent lawsuit with Nalu Medical
- 11/29/21
- Nevro announces 'important clinical data publications' for treating PDN with HFX
- 11/01/21
- Nevro announces update in Boston Scientific patent litigation, to pay $20M
- $10.07 /
-1.455 (-12.62%) - 01/07/22
- Neuropace Inc trading resumes
- 01/07/22
- Neuropace Inc trading halted, volatility trading pause
- 07/19/21
- Novanta buys privately held ATI Industrial Automation for $172M accretive deal
- 07/12/21
- Novanta to acquires Schneider Electric Motion USA for $115M in accretive deal
- 12/14/21
- Myriad Genetics promotes Nicole Lambert to COO
- 11/22/21
- Myriad Genetics to present new data at SABCS
- 10/18/21
- Myriad Genetics names Pamela Wong as Chief Legal Officer
- 09/07/21
- Illumina partners with Merck to develop, commercialize tests for cancer mutation
MRNS Marinus Pharmaceuticals - 12/03/21
- Marinus announces new clinical and research data to be presented at AES
- 09/20/21
- FDA accepts Marinus' filing and priority review of NDA for ganaxolone
- 08/17/21
- Marinus Pharmaceuticals reports topline ganaxolone Phase 2 results
- 08/03/21
- Marinus Pharmaceuticals submits ganaxolone NDA to FDA
- 12/12/21
- MorphoSys presents latest data from Phase 2 MANIFEST study
- 12/12/21
- MorphoSys, Incyte announce additional real-world evidence results from RE-MIND2
- 11/04/21
- MorphoSys presents interim results from M-PLACE study with felzartamab
- 11/02/21
- MorphoSys reports Q3 Monjuvi U.S. sales of $22M
- 12/12/21
- Molecular Partners confirms ensovibep retains Neutralization of omicron variant
- 12/06/21
- Molecular Partners presents results from ensovibep study for COVID-19 patients
- 12/03/21
- Molecular Partners enters MP0533 research collaboration with University of Bern
- 11/16/21
- Molecular Partners says ACTIV-3 has not met thresholds to continue enrollment
- 12/15/21
- ModivCare appoints Grover Wray as Chief Human Resources Officer
- 08/05/21
- Uber, ModivCare announce care-at-scale partnership
- 08/03/21
- ModivCare acquires VRI Intermediate Holdings for $315M
- 07/26/21
- ModivCare to acquire CareFinders Total Care for $340M
- 01/06/22
- Johnson & Johnson reports new results on durability of COVID-19 vaccines in U.S.
- 01/05/22
- SRI International announces collaboration agreement with Janssen
- 01/04/22
- Genocea announces R&D collaboration, option agreement with Janssen Biotech
JAZZ Jazz Pharmaceuticals - 01/05/22
- Jazz Pharmaceuticals: Lancet Neurology publishes positive Phase 3 data of Xywav
- 01/03/22
- Jazz Pharmaceuticals: FDA grants Orphan Drug Exclusivity for Xywav
- 12/30/21
- Jazz announces first patient enrolled in Phase 2 trial of JZP150
- 12/15/21
- Jazz Pharmaceuticals enrolls first patient in Phase 2b trial of suvecaltamide
- 12/06/21
- Inventiva reports results of QT study conducted with lanifibranor
- 10/27/21
- Inventiva announces design of LEGEND trial
- 09/21/21
- FDA extends prior fast track for lanifibranor for NASH to compensated cirrhosis
- 12/31/21
- Iteos to replace Magellan Health in S&P SmallCap 600 on 1/5
- 08/12/21
- iTeos Therapeutics expects cash to fund requirements into 2026
- 12/20/21
- Intra-Cellular jumps 18% to $46.30 after FDA approval of Caplyta
- 12/20/21
- Intra-Cellular announces FDA approval of Caplyta
- 10/18/21
- Intra-Cellular announces amended start time to October 20 virtual event
- 09/27/21
- Intra-Cellular announces publication of Phase 3 study of lumateperone
IART Integra LifeSciences - 10/28/21
- Integra LifeSciences appoints Jan De Witte as president, CEO
- 07/19/21
- Integra LifeSciences announces 'positive' clinical outcomes for PriMatrix
HZNP Horizon Therapeutics - 01/06/22
- Horizon Therapeutics to be tenant at Alexandria Center in Maryland
- 12/16/21
- Alpine Immune Sciences, Horizon Therapeutics enter exclusive license agreement
- 11/22/21
- Horizon Therapeutics publishes new post hoc analysis of Uplizna trial
- 11/15/21
- Paulson & Co. exits Dish, boosts Didi Global in Q3
- 12/22/21
- Gilead reports results from Phase 3 study of three-day course of Veklury
- 12/21/21
- Gilead announces clinical hold on studies of injectable Lenacapavir in HIV
- 12/21/21
- Gilead announces EC approval to variation of CMA for Veklury
- 12/16/21
- Gilead's Kite, Daiichi Sankyo to expand YESCARTA collaboration in Japan
- 01/04/22
- Endo's Par Pharma begins shipping first generic version of Merz's Cuvposa
- 12/23/21
- Endo announces pact to settle Texas opioid cases and claims
- 12/23/21
- Endo announces agreement for Paladin Labs to commercialize XCOPRI in Canada
- 12/15/21
- Eagle Pharmaceuticals receives FDA approval for Vasopressin
- 01/06/22
- Cathie Wood's ARK Investment bought 2.12M shares of Ginkgo Bioworks today
- 01/06/22
- Ginkgo Bioworks, Optimvia partner to manufacture biosynthetic heparin
- 01/05/22
- Ginkgo Bioworks falls -10.3%
- 12/19/21
- First North American detections of BA.3 sublineage of omicron variant confirmed
DAWN Day One Biopharmaceuticals - 11/22/21
- Day One announces first patient dosed in Phase 2 study of DAY101
- 09/13/21
- Day One Biopharmaceuticals appoints Jaa Roberson as CPO
- 08/17/21
- Day One Biopharmaceuticals appoints Scott Garland to board of directors
- 07/27/21
- Day One Biopharmaceuticals receives FDA Rare Pediatric Designation for DAY101
- 01/05/22
- Crinetics appoints Rogerio Vivaldi Coelho to board of directors
- 11/08/21
- Crinetics presents new data from OLE trial of paltusotine
- 10/18/21
- Crinetics forms new company for nonpeptide radiopharmaceuticals Radionetics
- 09/27/21
- Crinetics to present parathyroid receptor antagonist program at ASBMR meeting
- 10/20/21
- Viatris says Express Scripts to list Semglee as preferred on largest formulary
- 10/08/21
- Chubb to acquire life, non-life insurance companies of Cigna in APAC for $5.75B
- 10/01/21
- Cigna announces expansion of Medicare Advantage plans
- 09/28/21
- Procept BioRobotics announces Cigna adds Aquablation therapy to coverage policy
- 12/20/21
- Cerner trading resumes
- 12/20/21
- Oracle confirms agreement to acquire Cerner for $95.00 per share
- 12/20/21
- Oracle to buy Cerner for $95.00 per share in cash or $28.3B in equity value
- 12/20/21
- Cerner trading halted, news pending
- 12/23/21
- Conformis CLO, corporate secretary Brent Alldredge to depart
- 12/02/21
- Bruker says FluoroType SARS-CoV-2 varID Q assay detects all variants
- 12/02/21
- Bruker to replace KAR Auction in the S&P 400 at open on 12/2
- 12/02/21
- KAR Auction to replace Meredith in the S&P 600 at open on 12/2
- 01/05/22
- CDC expands Pfizer, BioNTech vaccine eligibility down to age 12
- 01/05/22
- Pfizer, BioNTech to partner on first mRNA-based shingles vaccine
- 01/04/22
- CDC shortens Pfizer vaccine booster interval to five months from six
- 01/03/22
- FDA authorizes Pfizer, BioNTech booster for 12 to 15 year olds
- 12/07/21
- Bright Health rises 20.4%
- 12/07/21
- Bright Health rises 18.5%
- 11/11/21
- Bright Health falls -25.0%
- 11/11/21
- Bright Health falls -20.5%
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 11/12/21
- Beam Therapeutics reports preclinical data for multiplex edited CAR T cells
- 10/19/21
- Sana obtains non-exlusive license to CRISPR Cas12b gene editing technology
- 10/19/21
- Beam Therapeutics reports new preclinical data for GSDIa new approach
- 12/20/21
- Alcoa to replace Hill-Rom in S&P 400 at open on 12/20
- 12/09/21
- Inspira Technologies signs summary distribution agreement with Innovimed
- 12/02/21
- Hillrom shareholders approve acquisition by Baxter
- 12/23/21
- Amyris completes JV with Minerva
- 10/05/21
- Amyris licenses Onyx genome engineering platform from Inscripta
- 09/07/21
- Amyris closes acquisition of Beauty Labs
- 08/31/21
- Amyris acquires MG Empower, terms not disclosed
ALLO Allogene Therapeutics - 12/15/21
- Allogene Therapeutics enters lease agreement to expand headquarters
- 12/01/21
- Allogene announces call to review ALPHA, ALPHA2, UNIVERSAL data
- 11/04/21
- Allogene Therapeutics to showcase clinical data at ASH annual meeting
- 10/07/21
- Allogene Therapeutics trading resumes
- 11/11/21
- Alkermes says first patient dosed in Phase 1 study of ALKS 1140
- 11/08/21
- Alkermes receives notices of partial termination from Janssen
- 10/27/21
- Alkermes reiterates its financial expectations for 2021
- 10/26/21
- Alkermes begins ARTISTRY-7 phase 3 trial
- $134.90 /
-0.2899 (-0.21%) - 01/07/22
- AbbVie submits applications to FDA, EMA seeking approvals for upadacitinib
- 01/05/22
- Aspira Women's Health announces fourth quarter operational metrics, updates
- 01/05/22
- Organon and Samsung Bioepis' sBLA for SB5 accepted by FDA
- 01/04/22
- AbbVie says FDA grants Breakthrough Therapy Designation to Teliso-V
- $134.90 /
-0.2899 (-0.21%) - 01/05/22 Mizuho
- Mizuho keeps AbbVie as top 2022 large cap pick, ups target
- 01/03/22 Piper Sandler
- AbbVie price target raised to $160 from $129 at Piper Sandler
- 12/17/21 Goldman Sachs
- AbbVie initiated with a Neutral at Goldman Sachs
- 12/08/21 Wells Fargo
- Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
ALLO Allogene Therapeutics - 01/06/22 Wells Fargo
- Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
- 01/03/22 Guggenheim
- Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
- 01/03/22 B. Riley
- iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
- 12/14/21 RBC Capital
- Allogene Therapeutics price target lowered to $35 from $45 at RBC Capital
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
- 01/07/22 Citi
- Baxter resumed with a Buy at Citi
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
- 01/04/22 Raymond James
- Baxter price target raised to $99 from $93 at Raymond James
- 01/07/22 Barclays
- Bright Health price target lowered to $5.50 from $9 at Barclays
- 12/17/21 Morgan Stanley
- Bright Health downgraded to Underweight at Morgan Stanley
- 12/16/21 Morgan Stanley
- Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/14/21 Goldman Sachs
- Bright Health initiated with a Neutral at Goldman Sachs
- 11/26/21 Benchmark
- Recent deals highlight value in ImmunoPrecise shares, says Benchmark
- 11/23/21 Baird
- Twist Bioscience price target lowered to $113 from $130 at Baird
- 10/14/21 Cowen
- Twist Bioscience coverage transferred at Cowen
- 08/09/21 Baird
- Twist Bioscience price target lowered to $130 from $140 at Baird
- 10/14/21 Cowen
- 10x Genomics coverage transferred at Cowen
- 09/14/21
- Fly Intel: Top five analyst downgrades
- 09/14/21 BofA
- 10x Genomics downgraded on 'incrementally more negative' tone at BofA
- 09/14/21 BofA
- 10x Genomics downgraded to Neutral from Buy at BofA
- 12/02/21 Baird
- Teladoc elevated to bullish Fresh Pick at Baird
- 12/01/21 Jefferies
- Teladoc assumed with a Hold at Jefferies
- 11/23/21 Canaccord
- Teladoc price target lowered to $160 from $188 at Canaccord
- 11/22/21
- Fly Intel: Top five analyst downgrades
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold from Buy at Jefferies
- 11/18/21 Piper Sandler
- Scholar Rock initiated with an Overweight at Piper Sandler
- 06/11/21 BMO Capital
- Scholar Rock coverage transferred at BMO Capital
- 09/24/21 Chardan
- Solid Biosciences price target lowered to $17 from $20 at Chardan
- 09/23/21 Piper Sandler
- Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
- 07/12/21 Piper Sandler
- Solid Biosciences initiated with a Neutral at Piper Sandler
- 07/09/21 Chardan
- Solid Biosciences coverage transferred at Chardan
- 01/03/22 Guggenheim
- Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
- 11/08/21 Jefferies
- Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
- 08/17/21 H.C. Wainwright
- Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
- 07/21/21 BofA
- BofA starts possible 'breakout star' Relay Therapeutics at Buy
- 10/20/21 Canaccord
- Quantum-Si initiated with a Buy at Canaccord
- 12/27/21 Raymond James
- Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
- 12/27/21 H.C. Wainwright
- Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
- 12/23/21 Evercore ISI
- Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
- 12/23/21
- Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals - 06/21/21 Cowen
- Cowen starts Day One with Outperform on glioma potential
- 06/21/21 JPMorgan
- Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 01/06/22 Monness Crespi
- Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
- 12/21/21 KeyBanc
- Cerner downgraded to Sector Weight from Overweight at KeyBanc
- 12/21/21 Deutsche Bank
- Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
- 12/21/21 KeyBanc
- KeyBanc downgrades Oracle, calls Cerner deal non-strategic
- 10/14/21 Cowen
- Bruker coverage transferred at Cowen
- 08/03/21 Wells Fargo
- Bruker price target raised to $85 from $70 at Wells Fargo
- 08/03/21 Citi
- Bruker price target raised to $85 from $75 at Citi
- 06/15/21 Cleveland Research
- Bruker upgraded to Buy from Neutral at Cleveland Research
- 12/22/21 Kempen
- BioNTech upgraded to Buy from Neutral at Kempen
- 12/21/21 H.C. Wainwright
- BioNTech price target raised to $366 from $360 at H.C. Wainwright
- 12/16/21 Morgan Stanley
- BioNTech initiated with an Equal Weight at Morgan Stanley
- 12/06/21 BofA
- BioNTech price target raised to $349 from $341 at BofA
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 10/19/21 SVB Leerink
- Beam Therapeutics initiated with an Outperform at SVB Leerink
- 09/23/21 Stifel
- Beam Therapeutics assumed at Buy from Hold at Stifel
- 01/04/22 JPMorgan
- MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
- 11/12/21 Morgan Stanley
- MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
- 09/27/21 Citi
- MorphoSys downgraded to Neutral from Buy at Citi
- 09/13/21 Goldman Sachs
- MorphoSys reinstated with a Neutral at Goldman Sachs
- 08/10/21 Credit Suisse
- Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
- 07/12/21 Cowen
- Molecular Partners initiated with an Outperform at Cowen
- 07/12/21 RBC Capital
- Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
- 07/12/21 SVB Leerink
- Molecular Partners assumed with an Outperform at SVB Leerink
- 12/17/21 Deutsche Bank
- ModivCare initiated with a Buy at Deutsche Bank
- 08/04/21 Barrington
- ModivCare price target raised to $186 from $170 at Barrington
- 05/10/21 Barrington
- ModivCare price target raised to $170 from $162 at Barrington
- 10/14/21 Cowen
- Myriad Genetics coverage transferred at Cowen
- 06/15/21
- Fly Intel: Top five analyst initiations
- 06/15/21 Raymond James
- Myriad Genetics initiated with a Market Perform at Raymond James
- 06/03/21 Goldman Sachs
- Myriad Genetics initiated with a Sell at Goldman Sachs
- 01/06/22 Wells Fargo
- Wells Fargo upgrades Cigna to Overweight, raises price target to $278
- 01/06/22 Wells Fargo
- Cigna upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/22 Truist
- Cigna price target raised to $275 from $270 at Truist
- 12/21/21
- Fly Intel: Top five analyst downgrades
- 11/30/21 JMP Securities
- Crinetics initiated with an Outperform at JMP Securities
- 11/23/21 Evercore ISI
- Evercore starts 'rare endo treasure trove' Crinetics at Outperform
- 11/23/21 Evercore ISI
- Crinetics initiated with an Outperform at Evercore ISI
- 06/18/21 JPMorgan
- Crinetics upgraded to Overweight ahead of data at JPMorgan
- 01/06/22 BTIG
- BTIG starts Ginkgo Bioworks at Buy with $12 price target
- 01/06/22 BTIG
- Ginkgo Bioworks initiated with a Buy at BTIG
- 11/29/21 Jefferies
- Ginkgo Bioworks initiated with a Buy at Jefferies
- 10/20/21 Raymond James
- Raymond James expects more equity-based payments for Ginkgo as milestones met
- 12/16/21 Barclays
- Endo price target lowered to $5 from $7 at Barclays
- 11/05/21 Stifel
- Endo's performance tempering 'noise' around litigation, says Stifel
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral from Overweight at Piper Sandler
- 12/29/21 Credit Suisse
- Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
- 12/17/21
- Fly Intel: Top five analyst initiations
- 12/17/21 Goldman Sachs
- Goldman starts Johnson & Johnson at Neutral amid disruption risk
- 12/17/21 Goldman Sachs
- Johnson & Johnson initiated with a Neutral at Goldman Sachs
- 01/06/22 Morgan Stanley
- Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/22/21 Piper Sandler
- Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
- 12/22/21 Morgan Stanley
- Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
- 12/15/21 Jefferies
- Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
- 12/01/21 Jefferies
- Health Catalyst initiated with a Hold at Jefferies
- 10/14/21 BTIG
- Health Catalyst initiated with a Buy at BTIG
- 08/10/21 RBC Capital
- Health Catalyst price target raised to $66 from $60 at RBC Capital
- 08/06/21 Canaccord
- Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics - 12/08/21
- Fly Intel: Top five analyst initiations
- 12/08/21 Wells Fargo
- Horizon Therapeutics initiated with an Overweight at Wells Fargo
- 11/18/21 Goldman Sachs
- Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
- 10/12/21 Evercore ISI
- Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences - 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
- 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
- 12/15/21 Citi
- Integra LifeSciences price target lowered to $70 from $78 at Citi
- 10/28/21 Piper Sandler
- Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals - 12/22/21 JPMorgan
- Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
- 12/20/21 SVB Leerink
- Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
- 12/17/21 Needham
- Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
- 11/18/21 Goldman Sachs
- Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 09/22/21 H.C. Wainwright
- Inventiva price target raised to $40 from $38 at H.C. Wainwright
- 05/04/21 Roth Capital
- Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
- 03/08/21
- Fly Intel: Top five analyst downgrades
- 12/16/21 Wedbush
- iTeos Therapeutics added to 'Best Ideas List' at Wedbush
- 12/13/21 H.C. Wainwright
- iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
- 11/11/21 Piper Sandler
- iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
- 06/14/21 Piper Sandler
- iTeos deal 'addresses a number of needs all at once, says Piper Sandler
- 12/21/21 RBC Capital
- Intra-Cellular price target raised to $55 from $50 at RBC Capital
- 12/21/21 Jefferies
- Intra-Cellular price target raised to $85 from $70 at Jefferies
- 12/20/21 Canaccord
- Intra-Cellular price target raised to $88 from $81 at Canaccord
- 12/20/21 SVB Leerink
- Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals - 08/18/21 Truist
- Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
- 03/10/21 H.C. Wainwright
- Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/06/22 UBS
- Singular Genomics price target lowered to $25 from $32 at UBS
- 10/14/21 Cowen
- Singular Genomics coverage transferred at Cowen
- 01/05/22 Piper Sandler
- Pacific Biosciences assumed with a Neutral at Piper Sandler
- 10/14/21 Cowen
- Pacific Biosciences coverage transferred at Cowen
- 09/27/21 Canaccord
- Pacific Biosciences initiated with a Buy at Canaccord
- 03/31/21 Piper Sandler
- Illumina should be bought on weakness from FTC challenge, says Piper Sandler
- 01/05/22 Stifel
- Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
- 11/03/21 Citi
- Ultragenyx trading at 'significant discount to fair value,' says Citi
- 09/30/21 H.C. Wainwright
- Ultragenyx initiated with a Buy at H.C. Wainwright
- 09/27/21 Piper Sandler
- Piper 'incrementally positive' on Ultragenyx after clinical hold lift
- 01/03/22 Guggenheim
- Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
- 11/10/21 Piper Sandler
- Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
- 09/14/21 Goldman Sachs
- Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
- 11/09/21 Roth Capital
- Amyris price target lowered to $15 from $22 at Roth Capital
- 10/14/21 Cowen
- Amyris coverage transferred at Cowen
- 08/06/21 H.C. Wainwright
- Amyris price target lowered to $30 from $35 at H.C. Wainwright
- 07/06/21 HSBC
- Amyris is at 'tipping point on growth,' says HSBC
- 12/01/21 Citi
- Alkermes initiated with a Neutral at Citi
- 11/09/21 Mizuho
- Alkermes price target lowered to $33 from $36 at Mizuho
- 10/28/21 Mizuho
- Alkermes shares have 25% upside after selloff, says Mizuho
- 10/28/21 H.C. Wainwright
- Alkermes price target raised to $30 from $25 at H.C. Wainwright
- $10.07 /
-1.455 (-12.62%) - 01/07/22 Morgan Stanley
- NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
- 01/07/22 Morgan Stanley
- NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/17/21 Baird
- NeuroPace price target lowered to $20 from $23 at Baird
- 11/11/21 Morgan Stanley
- Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/07/22 Piper Sandler
- Nevro price target raised to $92 from $90 at Piper Sandler
- 01/04/22 Piper Sandler
- Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
- 10/14/21 Cowen
- Seer coverage transferred at Cowen
- 08/13/21 Morgan Stanley
- Seer price target lowered to $50 from $55 at Morgan Stanley
- 04/14/21 Berenberg
- Shattuck Labs initiated with a Buy at Berenberg
- 01/20/21 Citi
- Shattuck Labs price target raised to $75 from $36 at Citi
- 01/11/21 Evercore ISI
- Shattuck Labs initiated with an Outperform at Evercore ISI
- 01/07/22 BofA
- Talis Biomedical downgraded to Underperform from Neutral at BofA
- 09/27/21 JPMorgan
- Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral at BTIG following CEO departure
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral from Buy at BTIG
- 11/03/21
- 10x Genomics narrows FY21 revenue view to $480M-$500M from $490M-$500M
- 11/03/21
- 10x Genomics reports Q3 EPS (15c), consensus (20c)
- 08/04/21
- 10x Genomics affirms 2021 revenue outlook $480M-$500M, consensus $496.49M
- 08/04/21
- 10x Genomics reports Q2 (10c), consensus (26c)
- 11/22/21
- Twist Bioscience sees FY22 revenue $173M-$181M, consensus $176.65M
- 11/22/21
- Twist Bioscience sees Q1 revenue $37M-$39M, consensus $38.78M
- 11/22/21
- Twist Bioscience reports Q4 EPS (84c), consensus (79c)
- 08/06/21
- Twist Bioscience raises FY21 revenue view to $129M-$132M from $121M-$129M
- 11/15/21
- Talis Biomedical reports Q3 EPS ($1.49), consensus ($1.40)
- 08/10/21
- Talis Biomedical reports Q2 EPS ($2.51), consensus (91c)
- 11/18/21
- Teladoc sees fiscal 2021 revenue $2.015B-$2.025B, consensus $2.02B
- 11/18/21
- Teladoc sees fiscal 2024 revenue above $4B
- 11/18/21
- Teladoc sees 2022 revenue $2.6B, consensus $2.58B
- 11/18/21
- Teladoc targets revenue growth of 25%-30% annually though 2024
- 11/09/21
- Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024
- 11/09/21
- Shattuck Labs reports Q3 EPS (41c), two estimates (44c)
- 11/09/21
- Scholar Rock reports Q3 EPS ($1.02), consensus (85c)
- 08/10/21
- Scholar Rock reports Q2 EPS (84c), consensus (78c)
- 11/03/21
- Solid Biosciences expects cash, cash equivalents to fund operations into Q2 2023
- 11/03/21
- Solid Biosciences reports Q3 collaborative revenue $3.5M vs. $0 last year
- 08/16/21
- Solid Biosciences reports Q2 revenue $3.6M, consensus $1.26M
- 11/09/21
- Seer reports Q3 EPS (30c), consensus (28c)
- 08/12/21
- Seer reports Q2 EPS (27c), consensus (28c)
- 11/10/21
- Relay Therapeutics reports Q3 EPS (66c), consensus (64c)
- 08/12/21
- Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c)
- 11/02/21
- Ultragenyx reports Q3 EPS ($1.08), consensus ($1.41)
- 08/02/21
- Ultragenyx reports Q2 EPS ($1.81), consensus ($1.36)
- 11/10/21
- Rain Therapeutics reports Q3 EPS (70c), consensus (48c)
- 08/10/21
- Rain Therapeutics reports Q2 EPS (39c), consensus (60c)
- 11/10/21
- Quantum-Si reports Q3 EPS (13c), one estimate (17c)
- 01/06/22
- Quidel reports preliminary Q4 revenue $633M-$637M, consensus $465.7M
- 11/04/21
- Quidel reports Q3 adjusted EPS $5.36, consensus $3.52
- 10/07/21
- Quidel sees Q3 revenue $505M-$510M, up 6%-7% from last year
- 08/10/21
- Cardinal Health partners with Abbott and Quidel to distribute COVID-19 tests
- 11/02/21
- Pacific Biosciences reports Q3 EPS (23c), consensus (22c)
- 08/03/21
- Pacific Biosciences reports Q2 EPS (21c), consensus (20c)
- 08/03/21
- Singular Genomics reports Q2 EPS ($1.18), consensus (20c)
- 11/08/21
- Nevro sees Q3 EPS ($1.44), consensus (87c)
- 08/05/21
- Nevro withdraws 2021 guidance due to Covid uncertainties
- 08/04/21
- Nevro sees Q3 revenue $90M-$93M, consensus $115.35M
- 08/04/21
- Nevro reports Q2 EPS (62c), consensus (73c)
- $10.07 /
-1.455 (-12.62%) - 08/12/21
- NeuroPace sees FY21 revenue view $47M, consensus $46.95M
- 08/12/21
- NeuroPace reports Q2 EPS (48c), consensus (34c)
- 11/09/21
- Novanta sees FY21 adjusted EPS $2.55-$2.62, consensus $2.45
- 11/09/21
- Novanta sees Q4 adjusted EPS 60c-67c, consensus 65c
- 11/09/21
- Novanta reports Q3 adjusted EPS 75c, consensus 60c
- 08/10/21
- Novanta sees FY21 adjusted EPS $2.30-$2.40, consensus $2.20
- 11/02/21
- Myriad Genetics not providing Q4, 2021 financial guidance
- 11/02/21
- Myriad Genetics reports Q3 adjusted EPS (2c), consensus (2c)
- 08/03/21
- Myriad Genetics not providing Q3, 2021 financial guidance
- 08/03/21
- Myriad Genetics reports Q2 adjusted EPS 12c, consensus (9c)
MRNS Marinus Pharmaceuticals - 11/09/21
- Marinus Pharmaceuticals lowers FY21 BARDA revenues view to $6M-$8M
- 11/09/21
- Marinus Pharmaceuticals reports Q3 EPS (53c), consensus (73c)
- 08/10/21
- Marinus Pharmaceuticals reports Q2 EPS (65c), consensus (69c)
- 07/26/21
- MorphoSys narrows FY21 revenue view to EUR 155M-EUR180M from EUR 150M-EUR 200M
- 11/05/21
- ModivCare reports Q3 cont-op EPS (53c), consensus
- 08/06/21
- ModivCare reports Q2 adjusted EPS $2.13, consensus $1.28
- 10/19/21
- Johnson & Johnson raises FY21 adjusted EPS view to $9.65-$9.70 from $9.50-$9.60
- 10/19/21
- Johnson & Johnson reports Q3 adjusted EPS $2.60, consensus $2.35
- 10/18/21
- Notable companies reporting before tomorrow's open
JAZZ Jazz Pharmaceuticals - 11/09/21
- Jazz narrows FY21 raises adjusted EPS view to $15.10-$15.80 from $13.40-$14.70
- 11/09/21
- Jazz Pharmaceuticals reports Q3 adjusted EPS $4.20, consensus $3.32
- 08/03/21
- Jazz reaffirms FY21 non-GAAP EPS view $13.40-$14.70, consensus $14.45
- 08/03/21
- Jazz Pharmaceuticals reports Q2 adjusted EPS $3.90, consensus $3.42
- 11/10/21
- iTeos Therapeutics reports Q3 EPS $1.98, consensus $4.95
- 08/12/21
- iTeos Therapeutics reports Q2 EPS (75c), consensus (41c)
- 11/09/21
- Intra-Cellular reports Q3 EPS (95c), consensus (92c)
- 08/09/21
- Intra-Cellular reports Q2 EPS (85c), consensus (80c)
IART Integra LifeSciences - 11/02/21
- Integra LifeSciences sees Q4 adjusted EPS 82c-86c, consensus 81c
- 11/02/21
- Integra LifeSciences raises FY21 EPS view to $3.16-$3.20 from $2.98-$3.05
- 11/02/21
- Integra LifeSciences reports Q3 adjusted EPS 86c, consensus 72c
- 07/28/21
- Integra LifeSciences sees Q3 adjusted EPS 71c-74c, consensus 74c
HZNP Horizon Therapeutics - 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
- 11/09/21
- Health Catalyst sees FY21 revenue $238.6M-$241.6M, consensus $239.02M
- 11/09/21
- Health Catalyst sees Q4 revenue $61.4M-$64.4M, consensus $62.75M
- 11/09/21
- Health Catalyst reports Q EPS (18c), consensus (22c)
- 08/05/21
- Health Catalyst sees Q3 revenue $59.4M-$62.4M, consensus $58.7M
- 10/28/21
- Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25
- 10/28/21
- Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74
- 10/28/21
- Notable companies reporting after market close
- 07/29/21
- Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45
- 11/04/21
- Endo raises FY21 adjusted EPS view to $2.80-$2.85 from $2.15-$2.30
- 11/04/21
- Endo reports Q3 adjusted EPS 80c, consensus 48c
- 08/05/21
- Endo narrows FY21 adjusted EPS to $2.15-$2.30 from $1.95-$2.30
- 08/05/21
- Endo reports Q2 cont-op adjusted EPS 65c, consensus 48c
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
DAWN Day One Biopharmaceuticals - 11/08/21
- Day One Biopharmaceuticals sees cash to fund operations into 2H of 2023
- 11/08/21
- Day One Biopharmaceuticals reports Q3 EPS (33c), consensus (28c)
- 08/10/21
- Day One Biopharmaceuticals reports Q2 EPS ($5.04), consensus (31c)
- 11/05/21
- Crinetics reports Q3 EPS (73c), consensus (72c)
- 12/27/21
- Cigna still sees FY21 adjusted EPS of at least $20.35, consensus $20.40
- 11/04/21
- Cigna sees FY22 EPS up at least 10% off increased FY21 guidance
- 11/04/21
- Cigna raises FY21 adjusted EPS view to at least $20.35 from at least $20.20
- 11/04/21
- Cigna reports Q3 adjusted EPS $5.73, consensus $5.22
- 10/29/21
- Cerner raises FY21 adjusted EPS view to $3.30 from $3.25, consensus $3.26
- 10/29/21
- Cerner sees Q4 adjusted EPS growth of 10%-13% over Q4 of 2020, consensus 88c
- 10/29/21
- Cerner reports Q3 adjusted EPS 86c, consensus 82c
- 10/28/21
- Notable companies reporting before tomorrow's open
- 11/01/21
- Bruker raises FY21 adjusted EPS view to $2.05-$2.09, consensus $1.93
- 11/01/21
- Bruker reports Q3 adjusted EPS 63c, consensus 44c
- 08/02/21
- Bruker reports Q2 EPS 44c, consensus 38c
- 08/02/21
- Bruker raises FY21 EPS outlook to $1.88-$1.93, consensus 1.89
- 11/09/21
- BioNTech sees 2021 COVID-19 vaccine revenues EUR 16B - EUR 17B
- 11/09/21
- BioNTech reports Q3 EPS EUR 12.35 vs. (EUR 0.88) last year
- 08/09/21
- BioNTech sees 2021 capex EUR 175M - EUR 225M
- 08/09/21
- BioNTech reports Q2 EPS EUR 10.77 vs. (EUR 0.38) last year
- 12/07/21
- Bright Health sees FY22 revenue $6.3B-$6.5B, consensus $5.87B
- 12/07/21
- Bright Health reaffirms FY21 revenue view of $4.1B-$4.2B, consensus $4.13B
- 11/11/21
- Bright Health sees FY21 revenue $4.1B-$4.2B, consensus $4.13B
- 11/11/21
- Bright Health reports Q EPS (48c), consensus (14c)
- 11/08/21
- Beam Therapeutics reports Q3 EPS (42c), consensus (74c)
- 08/10/21
- Beam Therapeutics reports Q2 EPS ($1.23), consensus (65c)
- 10/28/21
- Baxter sees Q4 EPS $1.00-$1.04, consensus $1.02
- 10/28/21
- Baxter sees FY21 EPS $3.58 to $3.62, consensus $3.52
- 10/28/21
- Baxter reports Q3 EPS $1.02, consensus 94c
- 07/29/21
- Baxter narrows FY21 adjusted EPS view to $3.49-$3.55 from $3.47-$3.55
- 11/08/21
- Amyris reports Q3 EPS (27c) vs. (41c) last year
ALLO Allogene Therapeutics - 11/04/21
- Allogene Therapeutics reports Q3 EPS (57c), consensus (56c)
- 08/04/21
- Allogene Therapeutics reports Q2 EPS (53c), consensus (55c)
- 10/27/21
- Alkermes reports Q3 adjusted EPS 15c, consensus 6c
- 07/28/21
- Alkermes raises FY21 non-GAAP EPS to 52c-70c from 37c-62c, consensus 51c
- 07/28/21
- Alkermes reports Q2 non-GAAP EPS 30c, consensus 12c
- $134.90 /
-0.2899 (-0.21%) - 10/29/21
- AbbVie sees FY21 revenue approaching $56.2B, consensus $56.28B
- 10/29/21
- AbbVie sees Q4 adjusted EPS $3.24-$3.28, consensus $3.30
- 10/29/21
- AbbVie raises FY21 adjusted EPS view to $12.63-$12.67 from $12.52-$12.62
- 10/29/21
- AbbVie reports Q3 adjusted EPS $3.33, consensus $3.22
|
|
Conference/Events
|
40th Annual Healthcare… 40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link ShowHide Related Items >><< - 07/27/21
- Bio-Rad and 10x Genomics announce settlement to resolve multiple litigations
- 07/27/21
- 10x Genomics enters into cross-license agreement with Bio-Rad
- 07/14/21
- 10x Genomics intoduces Chromium X Series for single cell analysis
- 01/05/22
- Twist Bioscience announces RBT-0813 neutralizes SARS-CoV-2 variants
- 12/16/21
- Twist Bioscience, Sosei Group announce GPCR collaboration
- 12/16/21
- Sosei Group enters agreement with Twist to discover, develop novel antibodies
- 12/15/21
- Twist shipping synthetic RNA positive controls for Omicron diagnostic tests
- 12/08/21
- Talis Biomedical CEO Blaser steps down, CCO Kelley to succeed
- 11/08/21
- Talis Biomedical granted FDA EUA for Talis One COVID-19 Test System
- 08/30/21
- Talis Biomedical CEO Brian Coe steps down, Kim Popovits named interim CEO
- 12/29/21
- Cathie Wood's ARK Investment bought 146.8K shares of Teladoc on Wednesday
- 12/28/21
- Cathie Wood's ARK Investment bought 123K shares of Teladoc on Tuesday
- 12/27/21
- Cathie Wood's ARK Investment sold 56.3K shares of Tesla on Monday
- 12/17/21
- Teladoc rises 10.6%
- 11/09/21
- Shattuck Labs announces preliminary clinical data from ongoing ARC trials
- 08/18/21
- Codiak appoints Lini Pandite to board of directors
- 11/30/21
- Scholar Rock announces design of phase 3 trial of Apitegromab in SMA
- 11/12/21
- Scholar Rock presents initial clinical data from Part A of DRAGON trial
- 09/28/21
- Scholar Rock announces issuance of U.S. patent protecting SRK-181
- 09/23/21
- Scholar Rock says added analyses 'further reinforce enthusiasm' for apitegromab
- 01/04/22
- Solid Biosciences reports inducement grant to SVP, human resources
- 11/02/21
- Pathway Development Consortium releases draft white paper
- 09/29/21
- Solid Biosciences reports additional pulmonary function results from IGNITE DMD
- 09/23/21
- Solid Biosciences' SGT-001 shows positive efficacy data at 1.5-year trial
- 11/04/21
- Seer drops 7% to $34.15 after Bear Cave short report
- 01/04/22
- Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion
- 12/10/21
- Relay Therapeutics announces preclinical data on RLY-2608
- 10/08/21
- Relay Therapeutics trading resumes
- 10/08/21
- Relay Therapeutics trading halted, volatility trading pause
- 01/07/22
- Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.
- 01/05/22
- Ultragenyx, GeneTx provide preliminary update on Phase 1/2 study of GTX-102
- 12/01/21
- Ultragenyx announces first patient dosed in Phase 1/2study of UX053
- 11/29/21
- Ultragenyx announces durability data from Phase 1/2 AAV gene therapy studies
- 01/05/22
- Rain Therapeutics, Roche to collaborate on trial of milademetan combination
- 12/14/21
- Rain Therapeutics added to Nasdaq Biotechnology Index
- 11/19/21
- Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan
- 11/10/21
- Rain Therapeutics announces anticipated milestones
- 11/09/21
- Quantum-Si acquires Majelac Technologies to secure chip supply chain
- 01/06/22
- Quidel CEO says looking ahead to launch of Savanna, closing Ortho deal in 2022
- 12/28/21
- Quidel confirm its antigen tests continue to detect COVID variants like omicron
- 12/23/21
- Quidel falls 12% to $146 after announcing $6B deal to acquire Ortho Clinical
- 12/23/21
- Quidel trading resumes
- 01/07/22
- Pacific Biosciences announces Radboudumc adds two new Sequel IIe Systems
- 01/06/22
- Pacific Biosciences expands fleet of HiFi applications with Azenta
- 01/05/22
- Pacific Biosciences, Care4Rare consortium collaborate on rare disease study
- 12/28/21
- PacBio says HiFiViral Surveillance kit performance not impacted by omicron
- 01/06/22
- Singular Genomics, Broad Institute partner to integrate technology in Terra
- 12/16/21
- Singular Genomics launches the G4 sequencing platform
- 01/04/22
- Nevro: UnitedHealth to provide coverage for company's treatment of PDN
- 12/21/21
- Nevro announces settlement of patent lawsuit with Nalu Medical
- 11/29/21
- Nevro announces 'important clinical data publications' for treating PDN with HFX
- 11/01/21
- Nevro announces update in Boston Scientific patent litigation, to pay $20M
- $10.07 /
-1.455 (-12.62%) - 01/07/22
- Neuropace Inc trading resumes
- 01/07/22
- Neuropace Inc trading halted, volatility trading pause
- 07/19/21
- Novanta buys privately held ATI Industrial Automation for $172M accretive deal
- 07/12/21
- Novanta to acquires Schneider Electric Motion USA for $115M in accretive deal
- 12/14/21
- Myriad Genetics promotes Nicole Lambert to COO
- 11/22/21
- Myriad Genetics to present new data at SABCS
- 10/18/21
- Myriad Genetics names Pamela Wong as Chief Legal Officer
- 09/07/21
- Illumina partners with Merck to develop, commercialize tests for cancer mutation
MRNS Marinus Pharmaceuticals - 12/03/21
- Marinus announces new clinical and research data to be presented at AES
- 09/20/21
- FDA accepts Marinus' filing and priority review of NDA for ganaxolone
- 08/17/21
- Marinus Pharmaceuticals reports topline ganaxolone Phase 2 results
- 08/03/21
- Marinus Pharmaceuticals submits ganaxolone NDA to FDA
- 12/12/21
- MorphoSys presents latest data from Phase 2 MANIFEST study
- 12/12/21
- MorphoSys, Incyte announce additional real-world evidence results from RE-MIND2
- 11/04/21
- MorphoSys presents interim results from M-PLACE study with felzartamab
- 11/02/21
- MorphoSys reports Q3 Monjuvi U.S. sales of $22M
- 12/12/21
- Molecular Partners confirms ensovibep retains Neutralization of omicron variant
- 12/06/21
- Molecular Partners presents results from ensovibep study for COVID-19 patients
- 12/03/21
- Molecular Partners enters MP0533 research collaboration with University of Bern
- 11/16/21
- Molecular Partners says ACTIV-3 has not met thresholds to continue enrollment
- 12/15/21
- ModivCare appoints Grover Wray as Chief Human Resources Officer
- 08/05/21
- Uber, ModivCare announce care-at-scale partnership
- 08/03/21
- ModivCare acquires VRI Intermediate Holdings for $315M
- 07/26/21
- ModivCare to acquire CareFinders Total Care for $340M
- 01/06/22
- Johnson & Johnson reports new results on durability of COVID-19 vaccines in U.S.
- 01/05/22
- SRI International announces collaboration agreement with Janssen
- 01/04/22
- Genocea announces R&D collaboration, option agreement with Janssen Biotech
JAZZ Jazz Pharmaceuticals - 01/05/22
- Jazz Pharmaceuticals: Lancet Neurology publishes positive Phase 3 data of Xywav
- 01/03/22
- Jazz Pharmaceuticals: FDA grants Orphan Drug Exclusivity for Xywav
- 12/30/21
- Jazz announces first patient enrolled in Phase 2 trial of JZP150
- 12/15/21
- Jazz Pharmaceuticals enrolls first patient in Phase 2b trial of suvecaltamide
- 12/06/21
- Inventiva reports results of QT study conducted with lanifibranor
- 10/27/21
- Inventiva announces design of LEGEND trial
- 09/21/21
- FDA extends prior fast track for lanifibranor for NASH to compensated cirrhosis
- 12/31/21
- Iteos to replace Magellan Health in S&P SmallCap 600 on 1/5
- 08/12/21
- iTeos Therapeutics expects cash to fund requirements into 2026
- 12/20/21
- Intra-Cellular jumps 18% to $46.30 after FDA approval of Caplyta
- 12/20/21
- Intra-Cellular announces FDA approval of Caplyta
- 10/18/21
- Intra-Cellular announces amended start time to October 20 virtual event
- 09/27/21
- Intra-Cellular announces publication of Phase 3 study of lumateperone
IART Integra LifeSciences - 10/28/21
- Integra LifeSciences appoints Jan De Witte as president, CEO
- 07/19/21
- Integra LifeSciences announces 'positive' clinical outcomes for PriMatrix
HZNP Horizon Therapeutics - 01/06/22
- Horizon Therapeutics to be tenant at Alexandria Center in Maryland
- 12/16/21
- Alpine Immune Sciences, Horizon Therapeutics enter exclusive license agreement
- 11/22/21
- Horizon Therapeutics publishes new post hoc analysis of Uplizna trial
- 11/15/21
- Paulson & Co. exits Dish, boosts Didi Global in Q3
- 12/22/21
- Gilead reports results from Phase 3 study of three-day course of Veklury
- 12/21/21
- Gilead announces clinical hold on studies of injectable Lenacapavir in HIV
- 12/21/21
- Gilead announces EC approval to variation of CMA for Veklury
- 12/16/21
- Gilead's Kite, Daiichi Sankyo to expand YESCARTA collaboration in Japan
- 01/04/22
- Endo's Par Pharma begins shipping first generic version of Merz's Cuvposa
- 12/23/21
- Endo announces pact to settle Texas opioid cases and claims
- 12/23/21
- Endo announces agreement for Paladin Labs to commercialize XCOPRI in Canada
- 12/15/21
- Eagle Pharmaceuticals receives FDA approval for Vasopressin
- 01/06/22
- Cathie Wood's ARK Investment bought 2.12M shares of Ginkgo Bioworks today
- 01/06/22
- Ginkgo Bioworks, Optimvia partner to manufacture biosynthetic heparin
- 01/05/22
- Ginkgo Bioworks falls -10.3%
- 12/19/21
- First North American detections of BA.3 sublineage of omicron variant confirmed
DAWN Day One Biopharmaceuticals - 11/22/21
- Day One announces first patient dosed in Phase 2 study of DAY101
- 09/13/21
- Day One Biopharmaceuticals appoints Jaa Roberson as CPO
- 08/17/21
- Day One Biopharmaceuticals appoints Scott Garland to board of directors
- 07/27/21
- Day One Biopharmaceuticals receives FDA Rare Pediatric Designation for DAY101
- 01/05/22
- Crinetics appoints Rogerio Vivaldi Coelho to board of directors
- 11/08/21
- Crinetics presents new data from OLE trial of paltusotine
- 10/18/21
- Crinetics forms new company for nonpeptide radiopharmaceuticals Radionetics
- 09/27/21
- Crinetics to present parathyroid receptor antagonist program at ASBMR meeting
- 10/20/21
- Viatris says Express Scripts to list Semglee as preferred on largest formulary
- 10/08/21
- Chubb to acquire life, non-life insurance companies of Cigna in APAC for $5.75B
- 10/01/21
- Cigna announces expansion of Medicare Advantage plans
- 09/28/21
- Procept BioRobotics announces Cigna adds Aquablation therapy to coverage policy
- 12/20/21
- Cerner trading resumes
- 12/20/21
- Oracle confirms agreement to acquire Cerner for $95.00 per share
- 12/20/21
- Oracle to buy Cerner for $95.00 per share in cash or $28.3B in equity value
- 12/20/21
- Cerner trading halted, news pending
- 12/23/21
- Conformis CLO, corporate secretary Brent Alldredge to depart
- 12/02/21
- Bruker says FluoroType SARS-CoV-2 varID Q assay detects all variants
- 12/02/21
- KAR Auction to replace Meredith in the S&P 600 at open on 12/2
- 12/02/21
- Bruker to replace KAR Auction in the S&P 400 at open on 12/2
- 01/05/22
- CDC expands Pfizer, BioNTech vaccine eligibility down to age 12
- 01/05/22
- Pfizer, BioNTech to partner on first mRNA-based shingles vaccine
- 01/04/22
- CDC shortens Pfizer vaccine booster interval to five months from six
- 01/03/22
- FDA authorizes Pfizer, BioNTech booster for 12 to 15 year olds
- 12/07/21
- Bright Health rises 20.4%
- 12/07/21
- Bright Health rises 18.5%
- 11/11/21
- Bright Health falls -25.0%
- 11/11/21
- Bright Health falls -20.5%
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 11/12/21
- Beam Therapeutics reports preclinical data for multiplex edited CAR T cells
- 10/19/21
- Sana obtains non-exlusive license to CRISPR Cas12b gene editing technology
- 10/19/21
- Beam Therapeutics reports new preclinical data for GSDIa new approach
- 12/20/21
- Alcoa to replace Hill-Rom in S&P 400 at open on 12/20
- 12/09/21
- Inspira Technologies signs summary distribution agreement with Innovimed
- 12/02/21
- Hillrom shareholders approve acquisition by Baxter
- 12/23/21
- Amyris completes JV with Minerva
- 10/05/21
- Amyris licenses Onyx genome engineering platform from Inscripta
- 09/07/21
- Amyris closes acquisition of Beauty Labs
- 08/31/21
- Amyris acquires MG Empower, terms not disclosed
ALLO Allogene Therapeutics - 12/15/21
- Allogene Therapeutics enters lease agreement to expand headquarters
- 12/01/21
- Allogene announces call to review ALPHA, ALPHA2, UNIVERSAL data
- 11/04/21
- Allogene Therapeutics to showcase clinical data at ASH annual meeting
- 10/07/21
- Allogene Therapeutics trading resumes
- 11/11/21
- Alkermes says first patient dosed in Phase 1 study of ALKS 1140
- 11/08/21
- Alkermes receives notices of partial termination from Janssen
- 10/27/21
- Alkermes reiterates its financial expectations for 2021
- 10/26/21
- Alkermes begins ARTISTRY-7 phase 3 trial
- $134.90 /
-0.2899 (-0.21%) - 01/07/22
- AbbVie submits applications to FDA, EMA seeking approvals for upadacitinib
- 01/05/22
- Aspira Women's Health announces fourth quarter operational metrics, updates
- 01/05/22
- Organon and Samsung Bioepis' sBLA for SB5 accepted by FDA
- 01/04/22
- AbbVie says FDA grants Breakthrough Therapy Designation to Teliso-V
- $134.90 /
-0.2899 (-0.21%) - 01/05/22 Mizuho
- Mizuho keeps AbbVie as top 2022 large cap pick, ups target
- 01/03/22 Piper Sandler
- AbbVie price target raised to $160 from $129 at Piper Sandler
- 12/17/21 Goldman Sachs
- AbbVie initiated with a Neutral at Goldman Sachs
- 12/08/21 Wells Fargo
- Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
ALLO Allogene Therapeutics - 01/06/22 Wells Fargo
- Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
- 01/03/22 Guggenheim
- Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
- 01/03/22 B. Riley
- iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
- 12/14/21 RBC Capital
- Allogene Therapeutics price target lowered to $35 from $45 at RBC Capital
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
- 01/07/22 Citi
- Baxter resumed with a Buy at Citi
- 01/07/22 Morgan Stanley
- Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
- 01/04/22 Raymond James
- Baxter price target raised to $99 from $93 at Raymond James
- 01/07/22 Barclays
- Bright Health price target lowered to $5.50 from $9 at Barclays
- 12/17/21 Morgan Stanley
- Bright Health downgraded to Underweight at Morgan Stanley
- 12/16/21 Morgan Stanley
- Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/14/21 Goldman Sachs
- Bright Health initiated with a Neutral at Goldman Sachs
- 11/26/21 Benchmark
- Recent deals highlight value in ImmunoPrecise shares, says Benchmark
- 11/23/21 Baird
- Twist Bioscience price target lowered to $113 from $130 at Baird
- 10/14/21 Cowen
- Twist Bioscience coverage transferred at Cowen
- 08/09/21 Baird
- Twist Bioscience price target lowered to $130 from $140 at Baird
- 10/14/21 Cowen
- 10x Genomics coverage transferred at Cowen
- 09/14/21
- Fly Intel: Top five analyst downgrades
- 09/14/21 BofA
- 10x Genomics downgraded on 'incrementally more negative' tone at BofA
- 09/14/21 BofA
- 10x Genomics downgraded to Neutral from Buy at BofA
- 12/02/21 Baird
- Teladoc elevated to bullish Fresh Pick at Baird
- 12/01/21 Jefferies
- Teladoc assumed with a Hold at Jefferies
- 11/23/21 Canaccord
- Teladoc price target lowered to $160 from $188 at Canaccord
- 11/22/21
- Fly Intel: Top five analyst downgrades
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
- 12/22/21 Jefferies
- Scholar Rock downgraded to Hold from Buy at Jefferies
- 11/18/21 Piper Sandler
- Scholar Rock initiated with an Overweight at Piper Sandler
- 06/11/21 BMO Capital
- Scholar Rock coverage transferred at BMO Capital
- 09/24/21 Chardan
- Solid Biosciences price target lowered to $17 from $20 at Chardan
- 09/23/21 Piper Sandler
- Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
- 07/12/21 Piper Sandler
- Solid Biosciences initiated with a Neutral at Piper Sandler
- 07/09/21 Chardan
- Solid Biosciences coverage transferred at Chardan
- 01/03/22 Guggenheim
- Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
- 11/08/21 Jefferies
- Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
- 08/17/21 H.C. Wainwright
- Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
- 07/21/21 BofA
- BofA starts possible 'breakout star' Relay Therapeutics at Buy
- 10/20/21 Canaccord
- Quantum-Si initiated with a Buy at Canaccord
- 12/27/21 Raymond James
- Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
- 12/27/21 H.C. Wainwright
- Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
- 12/23/21 Evercore ISI
- Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
- 12/23/21
- Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals - 06/21/21 Cowen
- Cowen starts Day One with Outperform on glioma potential
- 06/21/21 JPMorgan
- Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 06/21/21 Wedbush
- Day One Biopharmaceuticals initiated with an Outperform at Wedbush
- 01/06/22 Monness Crespi
- Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
- 12/21/21 KeyBanc
- Cerner downgraded to Sector Weight from Overweight at KeyBanc
- 12/21/21 Deutsche Bank
- Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
- 12/21/21 KeyBanc
- KeyBanc downgrades Oracle, calls Cerner deal non-strategic
- 10/14/21 Cowen
- Bruker coverage transferred at Cowen
- 08/03/21 Wells Fargo
- Bruker price target raised to $85 from $70 at Wells Fargo
- 08/03/21 Citi
- Bruker price target raised to $85 from $75 at Citi
- 06/15/21 Cleveland Research
- Bruker upgraded to Buy from Neutral at Cleveland Research
- 12/22/21 Kempen
- BioNTech upgraded to Buy from Neutral at Kempen
- 12/21/21 H.C. Wainwright
- BioNTech price target raised to $366 from $360 at H.C. Wainwright
- 12/16/21 Morgan Stanley
- BioNTech initiated with an Equal Weight at Morgan Stanley
- 12/06/21 BofA
- BioNTech price target raised to $349 from $341 at BofA
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 10/19/21 SVB Leerink
- Beam Therapeutics initiated with an Outperform at SVB Leerink
- 09/23/21 Stifel
- Beam Therapeutics assumed at Buy from Hold at Stifel
- 01/04/22 JPMorgan
- MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
- 11/12/21 Morgan Stanley
- MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
- 09/27/21 Citi
- MorphoSys downgraded to Neutral from Buy at Citi
- 09/13/21 Goldman Sachs
- MorphoSys reinstated with a Neutral at Goldman Sachs
- 08/10/21 Credit Suisse
- Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
- 07/12/21 Cowen
- Molecular Partners initiated with an Outperform at Cowen
- 07/12/21 RBC Capital
- Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
- 07/12/21 SVB Leerink
- Molecular Partners assumed with an Outperform at SVB Leerink
- 12/17/21 Deutsche Bank
- ModivCare initiated with a Buy at Deutsche Bank
- 08/04/21 Barrington
- ModivCare price target raised to $186 from $170 at Barrington
- 05/10/21 Barrington
- ModivCare price target raised to $170 from $162 at Barrington
- 10/14/21 Cowen
- Myriad Genetics coverage transferred at Cowen
- 06/15/21
- Fly Intel: Top five analyst initiations
- 06/15/21 Raymond James
- Myriad Genetics initiated with a Market Perform at Raymond James
- 06/03/21 Goldman Sachs
- Myriad Genetics initiated with a Sell at Goldman Sachs
- 01/06/22 Wells Fargo
- Wells Fargo upgrades Cigna to Overweight, raises price target to $278
- 01/06/22 Wells Fargo
- Cigna upgraded to Overweight from Equal Weight at Wells Fargo
- 01/05/22 Truist
- Cigna price target raised to $275 from $270 at Truist
- 12/21/21
- Fly Intel: Top five analyst downgrades
- 11/30/21 JMP Securities
- Crinetics initiated with an Outperform at JMP Securities
- 11/23/21 Evercore ISI
- Evercore starts 'rare endo treasure trove' Crinetics at Outperform
- 11/23/21 Evercore ISI
- Crinetics initiated with an Outperform at Evercore ISI
- 06/18/21 JPMorgan
- Crinetics upgraded to Overweight ahead of data at JPMorgan
- 01/06/22 BTIG
- BTIG starts Ginkgo Bioworks at Buy with $12 price target
- 01/06/22 BTIG
- Ginkgo Bioworks initiated with a Buy at BTIG
- 11/29/21 Jefferies
- Ginkgo Bioworks initiated with a Buy at Jefferies
- 10/20/21 Raymond James
- Raymond James expects more equity-based payments for Ginkgo as milestones met
- 12/16/21 Barclays
- Endo price target lowered to $5 from $7 at Barclays
- 11/05/21 Stifel
- Endo's performance tempering 'noise' around litigation, says Stifel
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
- 08/31/21 Piper Sandler
- Endo downgraded to Neutral from Overweight at Piper Sandler
- 12/29/21 Credit Suisse
- Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
- 12/17/21
- Fly Intel: Top five analyst initiations
- 12/17/21 Goldman Sachs
- Goldman starts Johnson & Johnson at Neutral amid disruption risk
- 12/17/21 Goldman Sachs
- Johnson & Johnson initiated with a Neutral at Goldman Sachs
- 01/06/22 Morgan Stanley
- Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/22/21 Piper Sandler
- Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
- 12/22/21 Morgan Stanley
- Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
- 12/15/21 Jefferies
- Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
- 12/01/21 Jefferies
- Health Catalyst initiated with a Hold at Jefferies
- 10/14/21 BTIG
- Health Catalyst initiated with a Buy at BTIG
- 08/10/21 RBC Capital
- Health Catalyst price target raised to $66 from $60 at RBC Capital
- 08/06/21 Canaccord
- Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics - 12/08/21
- Fly Intel: Top five analyst initiations
- 12/08/21 Wells Fargo
- Horizon Therapeutics initiated with an Overweight at Wells Fargo
- 11/18/21 Goldman Sachs
- Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
- 10/12/21 Evercore ISI
- Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences - 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
- 12/17/21 JPMorgan
- Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
- 12/15/21 Citi
- Integra LifeSciences price target lowered to $70 from $78 at Citi
- 10/28/21 Piper Sandler
- Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals - 12/22/21 JPMorgan
- Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
- 12/20/21 SVB Leerink
- Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
- 12/17/21 Needham
- Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
- 11/18/21 Goldman Sachs
- Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
- 11/22/21 H.C. Wainwright
- Inventiva price target raised to $42 from $40 at H.C. Wainwright
- 09/22/21 H.C. Wainwright
- Inventiva price target raised to $40 from $38 at H.C. Wainwright
- 05/04/21 Roth Capital
- Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
- 03/08/21
- Fly Intel: Top five analyst downgrades
- 12/16/21 Wedbush
- iTeos Therapeutics added to 'Best Ideas List' at Wedbush
- 12/13/21 H.C. Wainwright
- iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
- 11/11/21 Piper Sandler
- iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
- 06/14/21 Piper Sandler
- iTeos deal 'addresses a number of needs all at once, says Piper Sandler
- 12/21/21 RBC Capital
- Intra-Cellular price target raised to $55 from $50 at RBC Capital
- 12/21/21 Jefferies
- Intra-Cellular price target raised to $85 from $70 at Jefferies
- 12/20/21 Canaccord
- Intra-Cellular price target raised to $88 from $81 at Canaccord
- 12/20/21 SVB Leerink
- Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals - 08/18/21 Truist
- Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
- 03/10/21 H.C. Wainwright
- Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/07/22 BofA
- Singular Genomics upgraded to Buy from Neutral at BofA
- 01/06/22 UBS
- Singular Genomics price target lowered to $25 from $32 at UBS
- 10/14/21 Cowen
- Singular Genomics coverage transferred at Cowen
- 01/05/22 Piper Sandler
- Pacific Biosciences assumed with a Neutral at Piper Sandler
- 10/14/21 Cowen
- Pacific Biosciences coverage transferred at Cowen
- 09/27/21 Canaccord
- Pacific Biosciences initiated with a Buy at Canaccord
- 03/31/21 Piper Sandler
- Illumina should be bought on weakness from FTC challenge, says Piper Sandler
- 01/05/22 Stifel
- Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
- 11/03/21 Citi
- Ultragenyx trading at 'significant discount to fair value,' says Citi
- 09/30/21 H.C. Wainwright
- Ultragenyx initiated with a Buy at H.C. Wainwright
- 09/27/21 Piper Sandler
- Piper 'incrementally positive' on Ultragenyx after clinical hold lift
- 01/03/22 Guggenheim
- Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
- 11/10/21 Piper Sandler
- Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
- 09/14/21 Goldman Sachs
- Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
- 11/09/21 Roth Capital
- Amyris price target lowered to $15 from $22 at Roth Capital
- 10/14/21 Cowen
- Amyris coverage transferred at Cowen
- 08/06/21 H.C. Wainwright
- Amyris price target lowered to $30 from $35 at H.C. Wainwright
- 07/06/21 HSBC
- Amyris is at 'tipping point on growth,' says HSBC
- 12/01/21 Citi
- Alkermes initiated with a Neutral at Citi
- 11/09/21 Mizuho
- Alkermes price target lowered to $33 from $36 at Mizuho
- 10/28/21 Mizuho
- Alkermes shares have 25% upside after selloff, says Mizuho
- 10/28/21 H.C. Wainwright
- Alkermes price target raised to $30 from $25 at H.C. Wainwright
- $10.07 /
-1.455 (-12.62%) - 01/07/22 Morgan Stanley
- NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
- 01/07/22 Morgan Stanley
- NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/17/21 Baird
- NeuroPace price target lowered to $20 from $23 at Baird
- 11/11/21 Morgan Stanley
- Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
- 01/07/22 Morgan Stanley
- Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
- 01/07/22 Piper Sandler
- Nevro price target raised to $92 from $90 at Piper Sandler
- 01/04/22 Piper Sandler
- Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
- 10/14/21 Cowen
- Seer coverage transferred at Cowen
- 08/13/21 Morgan Stanley
- Seer price target lowered to $50 from $55 at Morgan Stanley
- 04/14/21 Berenberg
- Shattuck Labs initiated with a Buy at Berenberg
- 01/20/21 Citi
- Shattuck Labs price target raised to $75 from $36 at Citi
- 01/11/21 Evercore ISI
- Shattuck Labs initiated with an Outperform at Evercore ISI
- 01/07/22 BofA
- Talis Biomedical downgraded to Underperform from Neutral at BofA
- 09/27/21 JPMorgan
- Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral at BTIG following CEO departure
- 08/31/21 BTIG
- Talis Biomedical downgraded to Neutral from Buy at BTIG
|
